JPH0529014B2 - - Google Patents
Info
- Publication number
- JPH0529014B2 JPH0529014B2 JP60158481A JP15848185A JPH0529014B2 JP H0529014 B2 JPH0529014 B2 JP H0529014B2 JP 60158481 A JP60158481 A JP 60158481A JP 15848185 A JP15848185 A JP 15848185A JP H0529014 B2 JPH0529014 B2 JP H0529014B2
- Authority
- JP
- Japan
- Prior art keywords
- xanthine
- acetylsalicylic acid
- therapeutic agent
- carbon atoms
- agent according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 64
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 58
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims description 57
- 229960001476 pentoxifylline Drugs 0.000 claims description 50
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims description 42
- 239000003814 drug Substances 0.000 claims description 34
- 229940079593 drug Drugs 0.000 claims description 19
- -1 5-oxohexyl Chemical group 0.000 claims description 16
- 125000004432 carbon atom Chemical group C* 0.000 claims description 16
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 claims description 16
- 239000000306 component Substances 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 8
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 5
- 239000000651 prodrug Substances 0.000 claims description 5
- 229940002612 prodrug Drugs 0.000 claims description 5
- 239000012503 blood component Substances 0.000 claims description 4
- 239000003094 microcapsule Substances 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 239000002207 metabolite Substances 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- 229940075420 xanthine Drugs 0.000 claims description 3
- XBEDAMVJWVPVDS-UHFFFAOYSA-N 1,3-dimethyl-7-(5-oxohexyl)purine-2,6-dione Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2CCCCC(=O)C XBEDAMVJWVPVDS-UHFFFAOYSA-N 0.000 claims description 2
- NSMXQKNUPPXBRG-UHFFFAOYSA-N 1-(5-hydroxyhexyl)-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione Chemical compound O=C1N(CCCCC(O)C)C(=O)N(C)C2=C1N(C)C=N2 NSMXQKNUPPXBRG-UHFFFAOYSA-N 0.000 claims description 2
- HSUAWWZANQUYQS-UHFFFAOYSA-N 7-(5-hydroxyhexyl)-1,3-dimethylpurine-2,6-dione Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2CCCCC(O)C HSUAWWZANQUYQS-UHFFFAOYSA-N 0.000 claims description 2
- RBQOQRRFDPXAGN-UHFFFAOYSA-N Propentofylline Chemical compound CN1C(=O)N(CCCCC(C)=O)C(=O)C2=C1N=CN2CCC RBQOQRRFDPXAGN-UHFFFAOYSA-N 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 210000004051 gastric juice Anatomy 0.000 claims description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- MRWQRJMESRRJJB-UHFFFAOYSA-N pentifylline Chemical group O=C1N(CCCCCC)C(=O)N(C)C2=C1N(C)C=N2 MRWQRJMESRRJJB-UHFFFAOYSA-N 0.000 claims description 2
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims 12
- 239000003937 drug carrier Substances 0.000 claims 2
- DEDHQVXKYCLMFM-UHFFFAOYSA-N 8-propyl-3,7-dihydropurine-2,6-dione Chemical compound N1C(=O)NC(=O)C2=C1N=C(CCC)N2 DEDHQVXKYCLMFM-UHFFFAOYSA-N 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 description 29
- 241000700159 Rattus Species 0.000 description 17
- 230000002776 aggregation Effects 0.000 description 15
- 238000004220 aggregation Methods 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 208000007536 Thrombosis Diseases 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 210000000709 aorta Anatomy 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 230000002744 anti-aggregatory effect Effects 0.000 description 5
- 230000002917 arthritic effect Effects 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 239000013066 combination product Substances 0.000 description 5
- 229940127555 combination product Drugs 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 229940124531 pharmaceutical excipient Drugs 0.000 description 5
- 210000004623 platelet-rich plasma Anatomy 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000002785 anti-thrombosis Effects 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 3
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000002965 anti-thrombogenic effect Effects 0.000 description 3
- 210000002565 arteriole Anatomy 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 229960001123 epoprostenol Drugs 0.000 description 3
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- JJBCTCGUOQYZHK-UHFFFAOYSA-N 2-acetyloxybenzoate;(5-amino-1-carboxypentyl)azanium Chemical compound OC(=O)C(N)CCCC[NH3+].CC(=O)OC1=CC=CC=C1C([O-])=O JJBCTCGUOQYZHK-UHFFFAOYSA-N 0.000 description 2
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex⢠Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 210000002376 aorta thoracic Anatomy 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000013020 final formulation Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000003709 heart valve Anatomy 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 210000000264 venule Anatomy 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- CERFGCPAKWKZEK-UHFFFAOYSA-N 1-(5-hydroxyhexyl)-3-methyl-7-propylpurine-2,6-dione Chemical compound CN1C(=O)N(CCCCC(C)O)C(=O)C2=C1N=CN2CCC CERFGCPAKWKZEK-UHFFFAOYSA-N 0.000 description 1
- LJDSTRZHPWMDPG-UHFFFAOYSA-N 2-(butylamino)ethanol Chemical compound CCCCNCCO LJDSTRZHPWMDPG-UHFFFAOYSA-N 0.000 description 1
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000004475 Arginine Chemical class 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102220611780 Mitochondrial import inner membrane translocase subunit Tim23B_R95D_mutation Human genes 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- AKNUHUCEWALCOI-UHFFFAOYSA-N N-ethyldiethanolamine Chemical compound OCCN(CC)CCO AKNUHUCEWALCOI-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JPKKQJKQTPNWTR-BRYCGAMXSA-N [(1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfuric acid;hydrate Chemical compound O.OS(O)(=O)=O.C([C@H]1CC[C@@H](C2)N1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)N1C)C2OC(=O)C(CO)C1=CC=CC=C1 JPKKQJKQTPNWTR-BRYCGAMXSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 201000010435 allergic urticaria Diseases 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Chemical class OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000002473 artificial blood Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229960002028 atropine sulfate Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- YOUGRGFIHBUKRS-UHFFFAOYSA-N benzyl(trimethyl)azanium Chemical compound C[N+](C)(C)CC1=CC=CC=C1 YOUGRGFIHBUKRS-UHFFFAOYSA-N 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 231100000673 doseâresponse relationship Toxicity 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- AWKLBIOQCIORSB-UHFFFAOYSA-N etamiphylline Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2CCN(CC)CC AWKLBIOQCIORSB-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 238000001595 flow curve Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000021156 intermittent vascular claudication Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000012771 intravital microscopy Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229960004184 ketamine hydrochloride Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007942 layered tablet Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000006082 mold release agent Substances 0.000 description 1
- 230000009854 mucosal lesion Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
ïŒâïŒïŒâãªããœããã·ã«ïŒâïŒïŒïŒâãžã¡ãã«
ããµã³ãã³ïŒãã³ããã·ãã€ãªã³ïŒã¯è¡æ¶²ã®æµã
æ§è³ªãæ¹åããããã®è¬å€ãšããŠäœ¿çšãããããš
ãç¥ãããŠããããã®ããšã®æšå®ãããçç±ã¯
ãããã€ããš ã¡ãã€ã ããªãã³ã·ãŠãªããã
ïŒDeutsche Mediz.WochenschriftïŒç¬¬107巻第
1674é ïŒ1982幎ïŒããã³ããã·ãã€ãªã³ã§åŠçœ®ã
ãããšã«ããèµ€è¡çã®å€åœ¢å¯èœæ§ãæ¹åãããã®
ã§ãè¡æ¶²ã®ç²åºŠæµæãæžå°ãããšããããšã«ã
ããããã«è©Šéšç®¡å ã§è¡å°æ¿ã®åéããã³ããã·
ãã€ãªã³ã«ããæå¶ããããšã¯ã§ãããããã ã
ãã®ããšã¯å»åŠçæ²»çã§äœ¿çšããããããé«ãæ¿
床ã§ã®ã¿å¯èœã§ãããïœã¢ã€ã¢ãŒã«ã·ãŒãšã¹ïŒã¡
ãã ãµã€ïŒãIRCSïŒMed.Sci.ïŒã第ïŒå·»ç¬¬293é
ïŒ1980幎ïŒããããã³ãã¹ãã¢ã¹ã¿ã¹ã
ïŒãThrombos.Haemostas.ãïŒç¬¬46巻第272é
ïŒ1981幎ïŒïœã ããã«ãã³ããã·ãã€ãªã³ã«é¢ããŠã¯ãçäœå€
ã§ã®ã©ãã倧åèããã®æåé掻æ§ãæããç©è³ª
ã®æŸåºã¯ãã®åç©ããã³ããã·ãã€ãªã³ã§åŠçã
ãããšã«ããå¢å€§ã§ããããšãå ±åãããŠããã
åæ§ã«ãŸãæåé掻æ§ãæããç©è³ªã®æŸåºããã
ããããã¯åºæ¿ãããããšã«ããããã¹ã¿ãµã€ã¯
ãªã³ã®æŸåºã§ããããã©ãããã¢ã»ãã«ãµãªãã«
é žã§åŠçããããšã«ããæå¶ã§ããããšãç¥ãã
ãŠãããããµïŒãVasaãïŒç¬¬10巻第249é ïŒ1981
幎ïŒãã âã¢ã»ãã«ãµãªãã«é žã¯äººã®è¡å°æ¿åéé»å®³
å€ã§ããããšãç¥ãããŠãããããšãã°ããã«
ãžãšã€ ã¯ãªã³ ãã¢ãŒããã¯ãïŒãBr.J.Clin.
Pharmac.ãïŒç¬¬ïŒå·»ç¬¬283é ïŒ1979幎ïŒãããããŠ
ããã¯è¡æ çããã³çºäœãé»æ¢ããããšã«ããé
èŠãªæ²»çå¹æãçºæ®ã§ããããšãå ±åãããŠãã
ãããã©ãããïŒãBloodãïŒç¬¬52巻第1073é ïŒ1978
幎ïŒãããšã ã€ã³ã°ã« ãžãšã€ ã¡ãããïŒãN.
Engl.J.Med.ãïŒç¬¬299巻第53é ïŒ1978幎ïŒãããã®
äœçšæ©æ§ã¯ã¢ã»ãã«ãµãªãã«é žãè¡å°æ¿äžã«å±åš
ããé µçŽ ã·ã¯ããªãã·ã²ããŒãŒãé»å®³ããããžãš
〠ã¯ãªã³ ã€ã³ãã¹ããïŒãJ.Clin.Invest.ãïŒç¬¬
56巻第624é ïŒ1975幎ïŒãããããŠåéãä¿é²ãã
ããã³ãããµã³A2ã®çåæãæå¶ããããšã§ã
ããšå ±åãããŠãããããããªããã¢ã»ãã«ãµãª
ãã«é žã¯ãŸãè¡ç®¡å£ã«å±åšããã·ã¯ããªãã·ã²ã
ãŒãŒãé»å®³ããããšãã§ããåŸã€ãŠåéãé»å®³ã
ãããã¹ã¿ãµã€ã¯ãªã³ã®åæãé»å®³ããããšãã§
ãããããããªããè¡ç®¡ã®ã·ã¯ããªãã·ã²ããŒãŒ
ã®é»å®³ã¯é«æäžéã®ã¢ã»ãã«ãµãªãã«é žã«ãããŠ
ã®ã¿èªãããããããã¢ãŒãã³ã ãªãµãŒã ã³
ã³ããŠãŒã³ãïŒãPharmacol.Research
Commun.ãïŒç¬¬10巻第759é ïŒ1978幎ïŒãã®ã§ãåŸ
ã€ãŠæè¡æ 圢æäœçšãäœæäžéã®ã¢ã»ãã«ãµãªã
ã«é žãçšããŠéæããããšããããšãæšå¥šããã
ããã©ã³ã»ãããïŒãLancetãïŒç¬¬å·»ç¬¬1213é
ïŒ1979幎ïŒããããã¹ã¿ã°ã©ã³ãžã³ãº ã¢ã³ã ã¡
ãã€ã¹ã³ãïŒãProstaglandins and MedicineãïŒ
第ïŒå·»ç¬¬439é ïŒ1980幎ïŒããããããªãããŸãã¢
ã»ãã«ãµãªãã«é žã®æè¡æ 圢æäœçšã¯æäžéã®å¢
倧ãšãšãã«å¢å€§ããããã¹ã¿ãµã€ã¯ãªã³ããã³ã
ãã³ãããµã³ã®äž¡æ¹ã®çåæãå®è³ªçã«é»å®³ãã
ãããªæ¡ä»¶äžã§æ倧ã®å¹æãéæã§ãããšããå ±
åãããããããã¹ã¿ã°ã©ã³ãžã³ãº ãã€ã³ããª
ãšã³ãº ã¢ã³ã ã¡ãã€ã¹ã³ãïŒãProstaglandins
Leukotrienes and MedicineãïŒç¬¬12巻第235é
ïŒ1983幎ïŒãã äžæ¹ã§ã¯ã¢ã»ãã«ãµãªãã«é žã®ããããŠä»æ¹ã§
ã¯ããµã³ãã³èªå°äœã§ããïŒâïŒïŒâãžãšãã«ã¢
ãããšãã«ïŒããªãã€ãªã³ã®æå©ãªäœçšãããã
ãïŒçš®ã®åã ã®ç©è³ªã®é žâå¡©åºä»å äœã補é ãã
ããšã«ããäžç·ã«åããããããŠå»åŠã«ãããŠäœ¿
çšããããšããã§ã«é瀺ãããŠããïŒè±åœå ¬éç¹
èš±åºé¡ç¬¬2096138å·æ现æžïŒãããã«ãã³ããã·ã
ã€ãªã³ããã³ã¢ã»ãã«ãµãªãã«é žãçµã¿åãããŠ
åæã«æäžããå Žåã®ã人工å¿èåŒãæããæ£è
ã®è¡å°æ¿çåæéã«åãŒãäœçšãé瀺ãããŠãã
ããã·ã³ã¬ããŒã« ã¡ãã ãžã€ãŒãã«ã
ïŒãSingapore Med.Journalã第20å·»è£éºïŒç¬¬30é
ïŒ1979幎ïŒãã ä»ãã(A)äžæ¹ã§ããµã³ãã³èªå°äœãŸãã¯ããã
ã®æŽ»æ§ä»£è¬ç©ãããããŠ(B)ä»æ¹ã§ã¢ã»ãã«ãµãªã
ã«é žãŸãã¯ãã®è¬çåŠçã«èš±å®¹ãããå¡©ãäžå®ã®
æéçééã§ç¹å®ã®é åºã§é 次ã«æäžããããšã«
ãããé害ã®ããè¡æ¶²æåç¹ã«è¡å°æ¿ãŸãã¯èµ€è¡
çã«ãããããããŠãŸãçœè¡çã«ãããé害ã«ã
ãåŒãèµ·ããããé害ãŸãã¯ãããç¹åŸŽãšããé
害ã®æ²»çã極ããŠå€§ããæ¹åã§ããããšãèŠãåº
ããããé 次çæäžããªãã¡ããµã³ãã³èªå°äœç¹
ã«ãã³ããã·ãã€ãªã³ãæäžããã€ãã§10åéãª
ããïŒæéçµéããã®ã¡ã«ã¢ã»ãã«ãµãªãã«é žãŸ
ãã¯ãã®å¡©ãæäžããããšã«ããããããïŒçš®ã®
ããããã®ç©è³ªãçµåãããŠåæã«æäžããå Žå
ãããã¯ããã«å€§ããäœçšãåŸãããå®éã«åŸè
ã®å Žåã«ã¯ãã®äœçšãäœæžãããããµã³ãã³èªå°
äœããšãã°ãã³ããã·ãã€ãªã³ããã³ã¢ã»ãã«ãµ
ãªãã«é žãåæã«æäžããå Žåã«ã¯ã¢ã»ãã«ãµãª
ãã«é žãåç¬ã§æäžããå Žåã«åŸãããã®ãšåçš
床ã®æè¡æ 圢æäœçšããã³æåéäœçšãåŸããã
ã ãã§ããã®ã§ããã®ããšã¯å šãé©ãã¹ãããšã§
ããïŒä»¥äžã®è¡šïŒããã³ïŒãåç §ïŒã åŸã€ãŠæ¬çºæã¯(A)åŒïŒïŒãŸãã¯ïŒïŒïŒç¹èš±
è«æ±ã®ç¯å²ïŒãåç §ïŒã®ããµã³ãã³èªå°äœãŸãã¯
ãªããœã¢ã«ãã«âãŸãã¯ããããã·ã¢ã«ãã«ããµ
ã³ãã³ã®ãããã©ãã°ãŸãã¯ãããã®æŽ»æ§ä»£è¬
ç©ãããã³(B)âã¢ã»ãã«ãµãªãã«é žãŸãã¯ãã®
è¬çåŠçã«èš±å®¹ãããå¡©ã(C)è¬åŠç賊圢å€ãšãšã
ã«ããŸãã¯ããã䌎ããã«å«æããè¡æ¶²æåç¹ã«
è¡å°æ¿ãŸãã¯èµ€è¡çã ãã§ãªãããŸãçœè¡çã®æ
å·ã«ããåŒãèµ·ããããé害ãŸãã¯ãããç¹åŸŽãš
ããé害ãæ²»çããéã«ãæå(A)ãæåã«æŸåºã
ãããããªæ¹æ³ã§é 次ã«æäžããããã®çµåãã
çæç©ã«é¢ãããæèšããã°ãæ¬çºæã«ããè¬å€
ã¯ãããã®è¶ éå æçäœçšïŒsuperadditive
effectïŒã®ããã«æè¡æ 圢æãè¡æµä¿é²ãæç
çãé®çãæåéããã³çŽ°èå¢æ®æå¶ã®ããã®æ²»
çãŸãã¯äºé²ã«é©åœã§ãããåŸã€ãŠæ¬çºæã¯ãŸã
è¡æ¶²æåã®æå·ã«ããåŒãèµ·ããããé害ã®ãã
ã«ã(A)åŒãŸãã¯ã®ããµã³ãã³èªå°äœãŸãã¯åŒ
ããã³ã®ãªããœã¢ã«ãã«ããµã³ãã³ãŸãã¯åŒ
ã®ããããã·ã¢ã«ãã«ããµã³ãã³ã®ãããã©ã
ã°ã®åœ¢æ ããŸãã¯ãããã®ä»£è¬ç©ãããã³(B)â
ã¢ã»ãã«ãµãªãã«é žãŸãã¯ãã®è¬çåŠçã«èš±å®¹ã
ããå¡©ãã(C)é 次çã«æŸåºãããããªè¬å€ã補é
ããããã®è¬åŠç賊圢å€ãšãšãã«ããŸãã¯ããã
䌎ããã«ãæåãæåã«æŸåºãããããªæ¹æ³ã§
䜿çšããããšã«é¢ãããããã«æ¬çºæã¯ç¹èš±è«æ±
ã®ç¯å²ç¬¬ïŒé ã«èšèŒããããããªè¬åŠçåŠæ¹ç©ã®
補é ããã³äººå»åŠããã³ç£å»åŠã«ããããã®è¬å€
ã®äœ¿çšã«é¢ãããæ¬çºæã«ããçµåããçæç©ã¯
ã¢ã»ãã«ãµãªãã«é žãæŸåºããåã§ããããããµ
ã³ãã³èªå°äœãæŸåºããããããããšããããªã
ã¡çç©åŠçã«å©çšã§ããããã«ããããšãå¯èœã«
ããã ç¹ã«æå©ã§ããããšã¯é 次çã«æäžããããšã«
ããè¶ éå æçå¹æãåŸãããã®ã§ãæäžãã¹ã
ããµã³ãã³èªå°äœããã³ã¢ã»ãã«ãµãªãã«é žã®é
ããåç¬ã§æäžããå Žåã«ã¯æå°ã®è¬çåŠçäœçš
ãã瀺ããªããããªéãŸã§æžããããšãã§ããåŸ
ã€ãŠé«æäžéã®ãããã®è¬ç©ã«ããåŒãèµ·ããã
ãå¯äœçšãäœæžã§ããããšã§ãããã¢ã»ãã«ãµãª
ãã«é žã¯éåžžã®æäžéã§æãŸãããªãå¯äœçšãã
ãšãã°ãããªãã€ãã·ãŠ ãžã€ãŒãã« ãªã ã¯
ãªãã«ã« ãã¢ãŒãã³ããžãŒïŒãBritish Journal
of Clinical PharmacologyãïŒç¬¬10å·»è£éºïŒ
ïŒ1980幎ïŒãããã³æççå€ãé®çå€ã®å¯äœçšã«é¢
ããåœéåŠäŒïŒInternational Meeting on side
Effects of AntiinflammatoryãAnalgesic
DrugsïŒãŽãšããã1982幎ïŒæ13ã15æ¥ãèŠæšé
ã«åç §ãããããããšãã°åæ¯ãã¢ã¬ã«ã®ãŒæ§è
麻ç¹ãé®çå€æ§è èç çããã³æ¶åæ§æœ°çãåŒã
èµ·ããå¯èœæ§ãããããšãç¥ãããŠããã®ã§ãã®
ããšã¯æ¥µããŠéèŠã§ãããããã«ããµã³ãã³èªå°
äœã¯æãŸãããªãå¯äœçšã瀺ãå¯èœæ§ããããä»
ãé©ãã¹ãããšã¯æ¬çºæã«ããçµåããçæç©ã
çšããããšã«ãããããµã³ãã³èªå°äœã®éã°ãã
ã§ãªã人ã«å¯ŸããŠå¿ èŠãªã¢ã»ãã«ãµãªãã«é žã®æ
äžéã培åºçã«æžããããšãå¯èœã§ããã®ã§ãäž
è¬çãªæ¯ç©åŠç蚱容æ§ã«ãããŠããäžå±€å€§ããªæ¹
åããªããããããã«ã€ããŠã¯æŽã«äžèšãåç §ã
ãããã é©åœãªããµã³ãã³èªå°äœã®äŸã¯åŒããã ãåŒ
äžãåºR1ããã³R3ã®äžæ¹ã¯ïŒãïŒåã®ççŽ åå
ãæããçŽéã¢ã«ãã«ãïŒÏâïŒïŒâãªããœã¢ã«ã
ã«ãŸãã¯ïŒÏâïŒïŒâããããã·ã¢ã«ãã«åºã§ã
ãããããŠä»ã®ïŒåã®åºR2ããã³R3ãŸãã¯R1ã
ãã³R2ã¯ããããR1ããã³R3ã®äœçœ®ã«ïŒãïŒå
ã®ççŽ ååãããããŠR2ã®äœçœ®ã«ïŒãïŒåã®ç
çŽ ååãæãããããŠãããã®ïŒã€ã®ã¢ã«ãã«çœ®
æåºã«å«ãŸããççŽ ååã®åèšãæé«ã§10åã§ã
ããããªçŽéãŸãã¯åæéã¢ã«ãã«åºã§ãããã®
ïŒïŒïŒïŒïŒâããªçœ®æååç©ã§ããã ããã«ãããŠã¯å¥œãŸããåŒã®ããµã³ãã³åå
ç©ã¯R1ãŸãã¯R3ãïŒåãŸãã¯ïŒåãççŽ ååã
æããã¢ã«ãã«ãïŒÏâïŒïŒâãªããœã¢ã«ãã«ãŸã
ã¯ïŒÏâïŒïŒâããããã·ã¢ã«ãã«åºãè¡šããã
ãããŠïŒåã®ã¢ã«ãã«çœ®æåºR2ããã³R3ããŸã
ã¯R1ããã³R2ã¯äžç·ã«ãªã€ãŠïŒãïŒåã®ççŽ å
åãå«ããããªååç©ã§ããã ãããã®ååç©ã®ãã¡ã§ç¹ã«å¥œãŸãããã®ã¯
R1ãŸãã¯R3ã®äœçœ®ã«ããã·ã«ãïŒâãªããœãã
ã·ã«ãŸãã¯ïŒâããããã·ããã·ã«åºãæããå
åç©ã§ããããããã«ã¯ç¹ã«ïŒâããã·ã«âïŒïŒ
ïŒâãžã¡ãã«ããµã³ãã³ãïŒâïŒïŒâããããã·
ããã·ã«ïŒâïŒïŒïŒâãžã¡ãã«ããµã³ãã³ãïŒâ
ïŒïŒâãªããœããã·ã«ïŒâïŒïŒïŒâãžã¡ãã«ããµã³
ãã³ãïŒïŒïŒâãžã¡ãã«âïŒâïŒïŒâããããã·
ããã·ã«ïŒããµã³ãã³ãïŒïŒïŒâãžã¡ãã«âïŒâ
ïŒïŒâãªããœããã·ã«ïŒããµã³ãã³ãïŒâïŒïŒâã
ãããã·ããã·ã«ïŒâïŒâã¡ãã«âïŒâãããã«
ããµã³ãã³ããã³ïŒâïŒïŒâãªããœããã·ã«ïŒâïŒ
âã¡ãã«âïŒâãããã«ããµã³ãã³ãå«ãŸããã ããïŒã€ã®é©åœãªããµã³ãã³çŸ€ã¯åŒïŒãã ã
åŒäžãã¯ïŒãïŒåã®ççŽ ååãæããã¢ã«ãã«
åºãè¡šããïŒã®ååç©ããæãã åŒããã³ã®ãªããœã¢ã«ãã«ããµã³ãã³ãã
ã³åŒã®ããããã·ã¢ã«ãã«ããµã³ãã³ã«é¢ããŠ
ã¯ããèªäœã䜿çšããå¿ èŠã¯ãªããåŒããã³
ã«ãããŠå®çŸ©ããã眮æåºãæããæ²»çäžæŽ»æ§ãª
ããµã³ãã³ååç©ãäœå ã§åã«çäœå å€æã«ãã€
ãŠæŸåºã§ãããããªãããã©ãã°ã®åœ¢æ ã§ããã
ã䜿çšããããšãå¯èœã§ããããã®ããã«é©åœã§
ãããããã®äŸã¯ã«ã«ããã«åºãåŒïŒïŒïŒãã
ãåŒäžãR4ããã³R5ã¯ããããïŒåãŸã§ã®ççŽ
ååãæããã¢ã«ãã«åºãè¡šãããããŸãã¯äžç·
ã«ãªã€ãŠãšãã¬ã³ãããªã¡ãã¬ã³ãŸãã¯ããã©ã¡
ãã¬ã³åºãè¡šããïŒïŒç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé åç §ïŒ
ã®æ§é èŠçŽ ã«ãã眮æãããŠãããããªã¢ã»ã¿ãŒ
ã«åããããªããœã¢ã«ãã«ããµã³ãã³ãããã³ã
ãããã·ã«åºã®ä»£ããã«åŒR6âCOââïŒãã
ãåŒäžãR4ã¯ïŒåãŸã§ã®ççŽ ååãæããã¢ã«
ãã«åºãããšãã«ã眮æãããããšãã«ãããªãž
ã«ãŸãã¯çœ®æãããããªãžã«ãè¡šããïŒã®æ§é èŠ
çŽ ãæããâã¢ã·ã«åãããããããã·ã«ã¢ã«
ãã«ããµã³ãã³ã§ããã ã¢ã»ãã«ãµãªãã«é žã®é©åœãªè¬çåŠçã«èš±å®¹ã
ããå¡©ã¯è¬çåŠçã«èš±å®¹ãããéå±éœã€ãªã³ãã¢
ã³ã¢ããŠã ãã¢ãã³éœã€ãªã³ãŸãã¯ç¬¬ïŒçŽã¢ã³ã¢
ããŠã éœã€ãªã³ãšã®å¡©ã§ãããã¢ã«ã«ãªéå±ããš
ãã°ãªããŠã ããããªãŠã ããã³ã«ãªãŠã ããã³
ã¢ã«ã«ãªåé¡éå±ããšãã°ãã°ãã·ãŠã ããã³ã«
ã«ã·ãŠã ã®å¡©ã奜ãŸããããä»ã®éå±ããšãã°ã¢
ã«ãããŠã ãäºéããã³éã®éœã€ãªã³ã®åœ¢æ ã䜿
çšããããšãã§ããã è¬çåŠçã«èš±å®¹ãããã¢ãã³ã®éœã€ãªã³ã¯ç¬¬ïŒ
çŽã第ïŒçŽãŸãã¯ç¬¬ïŒçŽã¢ãã³ããšãã°ã¢ã«ãã«
ã¢ãã³ããšãã°ã¡ãã«âããžã¡ãã«âãããªã¡ã
ã«âããšãã«âããžããã«âãããªã€ãœãããã«
âãâã¡ãã«ããã·ã«âããã³ãžã«âãβâã
ãšãã«ãšãã«ã¢ãã³ããšãã¬ã³ãžã¢ãã³ããžãšã
ã¬ã³ããªã¢ãã³ããããªãžã³ãã¢ã«ããªã³ããã
ã©ãžã³ãã¢ãâããžâããã³ããªãšã¿ããŒã«ã¢ã
ã³ããšãã«ãžãšã¿ããŒã«ã¢ãã³ãâããã«ãšã¿
ããŒã«ã¢ãã³ãªã©ã®éœã€ãªã³ã§ãããä»ã®é©åœãª
ã¢ãã³ã®å¡©ã¯ãªãžã³ããã³ã¢ã«ã®ãã³ã®å¡©åºæ§ã¢
ãã³å¡©ã§ãããé©åœãªè¬çåŠçã«èš±å®¹ããã第ïŒ
çŽã¢ã³ã¢ããŠã éœã€ãªã³ã®äŸã¯ããã©ã¡ãã«ã¢ã³
ã¢ããŠã ãããã©ãšãã«ã¢ã³ã¢ããŠã ããã³ãã³
ãžã«ããªã¡ãã«ã¢ã³ã¢ããŠã ã§ããã äžæ¹ã®ããµã³ãã³èªå°äœãããã³ããäžæ¹ã®ã¢
ã»ãã«ãµãªãã«é žæåã¯ãŸãè¶ éå æçå¹æãé
æããããã«åæã«æäžããããšãã§ããããã
ãããšããããã®æåãéœåã®ããæéã«é 次ç
ã«æäžã§ãããããªãé©åœãªåœ¢æ ã®æ··åç©ã§ãã
ããšãã§ãããšããŠããå¥ã ã®åœ¢æ ã®è¬éåäœãš
ããŠæäžããã®ã奜ãŸãããè¬éåäœã¯åºäœç¶ã®
è¬å€åœ¢æ ããšãã°ã«ãã»ã«å€ïŒäžè¬çã«ã¯è¬åŠç
賊圢å€ãå«æããªããã€ã¯ãã«ãã»ã«ãå«ãïŒã
é å€ïŒè¢«èŠé å€ããã³äžžå€ãå«ãïŒãŸãã¯åå€ã®
圢æ ã§ããããšãã§ããããã«ãããŠã«ãã»ã«å€
ã䜿çšãããå Žåã«ã¯ã«ãã»ã«ç©è³ªã¯è³Šåœ¢å€ã®æ©
èœã瀺ããšèãããããããŠå 容ç©ã¯ããšãã°ç²
æ«ãã²ã«ãä¹³æ¿æ¶²ãåæ£ç©ãŸãã¯æº¶æ¶²ã®åœ¢æ ã§ã
ã€ãŠããããããããªããããããã®ææã®è¬åŠ
ç賊圢å€ãšãšãã«èšç®éã®æŽ»æ§ååç©ãå«æãã
ãããŠæŽ»æ§ååç©ã®æŸåºãé 次çã«çèµ·ãããã
ãªæ§è³ªãæãããïŒçš®ã®æŽ»æ§ååç©ã®çµå£çåŠæ¹
ç©ã®è£œé ããããšãç¹ã«æå©ã§ããããŸãç°¡åã§
ããããŸãçŽè žåŠçœ®ã®ããã®é©åœãªåŠæ¹ç©ïŒå
å€ïŒã䜿çšããããšãã§ãããåæ§ã«çµç®çãã
ã³éçµå£çïŒè ¹è å ãéèå ãç®äžãŸãã¯çè
å ïŒæ³šå°æ¶²ãå¯èœã§ããããã®å Žåã«ã¯ããšãã°
é©åœãªå€å®€æ³šå°è£ 眮ã䜿çšããããšãã§ããã ãã®åã®çµåããçæç©ã¯éåžžã®æ¹æ³ã«ãã補
é ããããšãã§ãããæ¬çºæã«ãã掻æ§ååç©ã®
é 次çæŸåºïŒçäœå å©çšçïŒã¯éåžžã®æ¹æ³ã§ãã
ãšãã°ãµãã«ãŒãããã¯ã¹ããã³ã¹ãã€ãµãŒèã
ã¢ãŒãããªã€ãã€ãã·ãš ãã¯ããã®ãš
ãSuckerãFuchsããã³Speiserè
ãPharmazeutische TechnologieãïŒè¬åŠæè¡ïŒã
第424é ïŒ1978幎çºè¡ãã·ãŠã¿ããã¬ã«ãïŒã«åŸ
ã€ãŠãå»è¬ãšããŠã¢ã»ãã«ãµãªãã«é žãŸãã¯ãã®
å»åŠçã«èš±å®¹ãããå¡©ããšãã°ïŒ€ïŒïŒ¬âãªãžã³ã¢
ãã¢ã»ãã«ãµãªã·ã¬ãŒããå«æããé å€ãäžžå€ãŸ
ãã¯é¡ç²å€ããæå©ã«ã¯ç²æ¶²åæ³æ§ç©è³ªãæš¹èã
ãšãã°ããªã¹ãã¬ã³ãŸãã¯èš±å®¹æ§ãä¿é²ããä»ã®
é垞䜿çšãããè¬å€ãšçµåãããŠæŽ»æ§ååç©ãšã
ãŠããšãã°ãã³ããã·ãã€ãªã³ãå«æããã³ãŒã
ã€ã³ã°ïŒå€ç®ïŒã§è¢«èŠããããšã«ããéæã§ã
ããè¯éšåãšããŠäœ¿çšãããé å€ãäžžå€ãŸãã¯é¡
ç²å€ã¯éåžžã®æ¹æ³ã«ãã補é ããããšãã§ããã
ããŠè³Šåœ¢å€ããã³ä»ã®é垞䜿çšãããè£å©å€ããš
ãã°æŸ±ç²ããšãã°ãããããããšããããããŸã
ã¯å°éºŠã®æŸ±ç²ãã»ã«ããŒã¹ãŸãã¯ãã®èªå°äœç¹ã«
埮æ¶æ§ã»ã«ããŒã¹ãã·ãªã«ãçš®ã ã®ç³ããšãã°ä¹³
ç³ãçé žãã°ãã·ãŠã ããã³ïŒãŸãã¯çé žã«ã«ã·
ãŠã ãå«æããããšãã§ãããããšãã°ãã³ãã
ã·ãã€ãªã³ãå«æããå€ç®ã¯ããšãã°è¬åŠçæè¡
ã«ãããŠé垞䜿çšãããæ¹æ³ããšãã°å§çž®ã液浞
ãŸãã¯æµååºæ³ã«ããããŸãã¯ãã©ã ã³ãŒãã€ã³
ã°ã«ããè¯éšåã«é©çšããããšãã§ãããå€ç®ã®
溶液ã¯éåžžãŒã©ãã³ãã¢ã©ãã¢ãŽã ãããªããã«
ãããªãã³ãåæã»ã«ããŒã¹ãšã¹ãã«ãè¡šé¢æŽ»æ§
ç©è³ªãå¯å¡å€ãè²çŽ ããã³åœæ¥ã«ãããŠäœ¿çšãã
ãåæ§ã®ä»å ç©ãæ·»å ããç³ããã³ïŒãŸãã¯æŸ±ç²
ã·ãããããæãã 掻æ§ååç©ã®é 次çæŸåºã¯ãŸããµãã«ãŒæ°ã
ïŒäžèšæç®åç §ïŒã«ããåæ§ã«èšèŒãããŠããã
ããªéå±€é ïŒãã®çšèªã«ã¯åå¿æ§è¯é å€ãå«ãŸã
ãïŒã䜿çšããããšã«ããéæã§ãããã®å Žåã
ãæ©ãåžåãããå±€ã¯æå©ã«ã¯åæ§ã«ç²æ¶²åæ³æ§
ç©è³ªãŸãã¯ä»ã®èš±å®¹æ§ãä¿é²ããéåžžã®è¬å€ãšãš
ãã«ããµã³ãã³ãå«æããããã®è¬å€ã®åœ¢æ ã«ã
ããŠã¯ã掻æ§ååç©ã®æŸåºã¯é垞䜿çšãããé©åœ
ãªè£å©å€ããšãã°äžèšã«è©³è¿°ããããã®ã䜿çšã
ãŠé å€ã®å±€ããã®æŸåºé床ã«å·®ãçããããããš
ã«ããéæã§ãããïŒçš®ã®æŽ»æ§ååç©ããšãã°ã
ã³ããã·ãã€ãªã³ããã³ã¢ã»ãã«ãµãªãã«é žã®æ®µ
éçãªæŸåºã¯ããŸãã¢ã»ãã«ãµãªãã«é žãå«æã
ãæåãé 延å€ãå«æããããšã«ãã€ãŠãéæã
ãããã®é 延å€ã¯é©åœãªå Žåã«ã¯ããšãã°ã»ã«ã
ãŒã¹ãŸãã¯ããªã¹ãã¬ã³æš¹èãŸãã¯ã€ãªã³äº€æäœ
ã«åºã¥ãã浞éèã®åœ¢æ ã§äœ¿çšããŠãããããŸã
è液ã«æµæããããŸãã¯æŸåºãé ããããããªã
ã€ã¯ãã«ãã»ã«ã®åœ¢æ ã§äœ¿çšããŠããããããã
ãªããã¢ã»ãã«ãµãªãã«é žãå«æããè¯éšåã¯ãŸ
ãæŸåºãé ãããããšãã§ãããããªãããšãã°
ããªã¡ã¿ã¯ãªã«ãšã¹ãã«ïŒãŠãŒãã©ã®ããã
Eudragit(R)ãå«ãã³ãŒãã€ã³ã°ãæœãããšãã§ã
ãã é垞䜿çšããããã¹ãŠã®æµã調ç¯å€ããªããã
ã«ããè¬å€ããªãã¡æœ€æ»å€ããšãã°ã¹ãã¢ãªã³é ž
ãã°ãã·ãŠã ãããã³é¢åå€ããã®è¬å€åœ¢æ 補é
ã®ããã«äœ¿çšããããšãã§ããã ã¢ã»ãã«ãµãªãã«é žã®ããµã³ãã³èªå°äœããšã
ã°ãã³ããã·ãã€ãªã³ã«å¯Ÿããééæ¯ã¯åºãç¯å²
å ã§å€ããããšãã§ãããç¹å®ã®çµåããã«å¯Ÿã
ãŠäœ¿çšãããæ£ç¢ºãªå²åã¯äžèšã®å®éšæäœã䜿çš
ããŠå®¹æã«æ±ºå®ããããšãã§ãããäžè¬çã«ã¯ã¢
ã»ãã«ãµãªãã«é žïŒéééšã«å¯Ÿããããµã³ãã³èª
å°äœããšãã°ãã³ããã·ãã€ãªã³ã®ééæ¯ã¯æäœ
çŽ0.1奜ãŸããã¯æäœçŽ0.3ã0.5ãç¹ã«æäœçŽïŒã
ãæé«çŽ50奜ãŸããã¯æé«çŽ10ãŸã§ã§ããããŸã
ããµã³ãã³èªå°äœã®æäžããã³ã¢ã»ãã«ãµãªãã«
é žã®æäžãšã®æé©ã®æéééããŸãã¯è¬åŠçåŠæ¹
ç©ããã®æé©ã®æŸåºé床ã決å®ããããšãããã
ã®å®éšæäœã䜿çšããããšã«ããå¯èœã§ãããã
ãµã³ãã³èªå°äœããšãã°ãã³ããã·ãã€ãªã³ãæ
åã«æŸåºããããããã€ãã«15åãªããïŒæéåŸ
ã«ã¢ã»ãã«ãµãªãã«é žæåãæŸåºããããããã
çŽ20ã90åããããŠç¹ã«30ã60åã®ééãç¹ã«å¥œ
ãŸããããã¡ããæäžãããè¬éã¯çš®ã ã®å åã
ãšãã°åŠçãããçç©äœïŒããªãã¡äººãŸãã¯å
ç©ã幎什ãäœéããã³äžè¬çãªå¥åº·ç¶æ ïŒãçç¶
ã®é節ããæ²»çãã¹ãçŸæ£ãïŒååšããå Žåã«ã¯ïŒ
ä»ã®è¬å€ãçšããŠã®åææ²»çã®æ§è³ªãæ²»çåæ°ãª
ã©ã«ããäžèšã®è¬éã¯äžè¬çã«ïŒæ¥ã«ïŒåãŸã§ã
ãããŠå¥œãŸããã¯ïŒæ¥ã«ïŒåãïŒåæäžãããã
ããããã®æŽ»æ§ååç©ã®ééæ¯ã¯äžèšã«ç€ºããã
ç¯å²å ã«å ¥ãã¹ãã§ãããæåã®éã¯äžèšã«ç€ºã
ããç¯å²å ã«å ¥ãã¹ãã§ããããããŠæåã®éã¯
æ²»çãããçäœã蚱容ããããããªæå¹æäžéã®
ç¯å²å ã«ããã¹ãã§ããã ããšãã°ã¢ã»ãã«ãµãªãã«é žã®å¥œãŸããæäžé
ã¯ã人ã«åç¬ã§æäžããå Žåã500ã2000mgç¹ã«
1000mgã§ãããïŒæ¥ã«ïŒãïŒåæäžãããããã³
ããã·ãã€ãªã³ã®å¥œãŸããæäžéã¯ã人ã«åç¬ã§
æäžããå Žåã200ã800mgç¹ã«300ã600mgã§ã
ããïŒæ¥ã«ïŒãïŒåæäžãããã ãã¢ã»ãã«ãµãªãã«é žã®ãã³ããã·ãã€ãªã³ã«å¯Ÿ
ãããããã®ééæ¯ããé©åãªéãæ£ç¢ºã«èšç®ã
ãããšãã§ãããåŸã€ãŠé©åœãªæ²»çã¯æ¬çºæã«ã
ãçµåããçæç©ã®åç¬æäžããšãã°ïŒåãïŒå
ãŸãã¯æ°å奜ãŸããã¯ïŒãïŒåæäžããããšãã
æãããã®åç¬æäžéã¯ããããããµã³ãã³èªå°
äœç¹ã«ãã³ããã·ãã€ãªã³ã100ã600mgã奜ãŸã
ãã¯æäœ200mgããããŠç¹ã«400mgãŸã§ãå«æãã
ãããŠã¢ã»ãã«ãµãªãã«é žã10ã2000mgããšãã°
400mgãŸã§ãå«æããããŸãã¯ããã«çžåœããé
ã®å¡©ãå«æããããã®å Žåã«ãã®éã¯ãã¡ããå
ç¬æäžã®åæ°ãªãã³ã«æ²»çãããã¹ãçŸæ£ã«ãã€
ãŠç°ãªãããããŠåç¬æäžã¯ããšãã°åæã«æäž
ãããæ°åã®é å€ãå«ãããšãã§ãããããããª
ããæ¬çºæã«ãããŸãç¹ã«å°éã®ã¢ã»ãã«ãµãªã
ã«é žïŒããšãã°ïŒæ¥ããã10ã50mgãŸãã¯ãã以
äžïŒã®æäžãææãããå Žåã«è¯å¥œãªçµæãåŸã
ããšãã§ããããã«ãªãããã®çµæã¯åéã®ã¢ã»
ãã«ãµãªãã«é žãåç¬ã§æäžããå Žåããããªã
è¯å¥œã§ããã æ¬çºæã«ããè¬å€ã¯æ¢ç¥ã®æè¡æ 圢æå€ããã³
è¡å°æ¿åéé»å®³å€ãšåæ§ã®æ¹æ³ã§äœ¿çšããããšã
ã§ãããçäœå ã§ã®äœ¿çšã¯åèããã³éèã§ã®è¡
é€ åœ¢æãé»æ¢ããããã«ãããšãã°äžæçãªèè¡
æ§çºäœãé»æ¢ããããã«ããããŠå¿çæ¢å¡ããã³
çºäœåŸã®ããããŠåè硬åçã®é·æçäºé²ã®ãã
ã«ããããŠãŸãå€ç§æè¡åŸã®è¡æ çãé²æ¢ããã
ãã®åŠçœ®ãšããŠããŸã転移ãé»æ¢ãŸãã¯äœæžãã
ããã®çã®åŸåŠçœ®ãšããŠäººããã³åç©ã«æäžãã
ããšããæãã 人工å¿èºè£ 眮ãæããæ£è ããã³è èéæãšé¢
ä¿ã®ããæ£è ãžã®æäžãå¯èœã§ãããåæ§ã«äººå·¥
å¿èåŒã人工è¡ç®¡ãªã©ãæããæ£è ãžã®æäžãå¯
èœã§ããããã¡ããäžèšã®ããããã®æåã¯ããš
ãã°è¡æµä¿é²ïŒéæ¬ æ§è·è¡ïŒããã³é®çããã³æ
ççäœçšïŒæ ¢æ§çççãå«ãïŒã®ããã®å®éäžã®
æ瀺ã«åŸã€ãŠæäžããããšãã§ãããæççæ§ã®
補å€ã®å Žåã«ã¯ããµã³ãã³èªå°äœã®æåã«å¯Ÿã
ãæ¯ã¯äžè¬çã«0.1ãïŒã§ããããä»æ¹ä»ã®è£œå€
ã®å Žåã«ã¯äžè¬çã«ããã¯0.5ã50ã§ããã çäœå ã«ãããç 究 ãã³ããã·ãã€ãªã³ããã³ã¢ã»ãã«ãµãªãã«é ž
ã®çµåããã¯ã¬ãŒã¶ãŒãçšããŠã©ããè žéèã®å°
åèã«ãããŠè¡ç®¡å è¡æ çãåŒãèµ·ãããããªå®
éšèšç»ã䜿çšããŠçäœå ã§è©äŸ¡ãããããã®æ¹æ³
ã¯æ¬çºæã«ããçµåããçæç©ã«å¯Ÿããé©åœãªå®
éšã¢ãã«ã§ãããçäœé¡åŸ®é¡æ€æ»æ³ãçšããåæ
ã«ããè©äŸ¡ãè¡ããããããã€ãã€ãŒãïŒ
ïŒãNatureãïŒç¬¬218巻第887é ïŒ1968幎ïŒããã³
ããã¢ã¹ã¿ã·ã¹ãïŒãHaemostasisãïŒç¬¬13巻第61é
ïŒ1983幎ïŒããã³ãã¢ã€ã¢ãŒã«ã·ãŒãšã¹ ã¡ãã
ãµã€ãïŒãIRCS Med.Sci.ãïŒç¬¬12巻第91é
ïŒ1984幎ïŒãã è©Šéšç©è³ªã¯0.9ïŒ å¡©åãããªãŠã 溶液ãããã¯
ïŒïŒ ã«ã«ããã·ã¡ãã«ã»ã«ããŒã¹ããµãŒã瀟補
ïŒServaïŒããã€ãã«ãã«ã°ããå«æããŠããããš
ããŠçµå£çã«ããè ¹è å ã«ããŸãã¯éèå ã«æäž
ãããå¯Ÿç §åç©ã¯è©Šéšç©è³ªãçšããã«å¯Ÿå¿ããæ¹
æ³ã§åŠçããã䜿çšããå®éšåç©ã¯éæ§ãŸãã¯é
æ§ã®ã¹ãã¬ã€ã°âããŠã¬ã€ç³»ãŸãã¯ãŠã€ã¹ã¿ãŒç³»
ã©ããã§ãã€ãã ã¬ãŒã¶ãŒã§åŒãèµ·ããããè¡æ çã¢ãã«ã«ãã
ãŠãã³ããã·ãã€ãªã³ãä»ã®ããµã³ãã³èªå°äœã
ãã³ã¢ã»ãã«ãµãªãã«é žãçšããç 究ã¯äœéçŽ
200ïœã®éæ§ã¹ãã¬ã€ã°âããŠã¬ã€ç³»ã©ããã«ã
ããŠè¡ããããç 究ãããåç©ã«0.1mgã®ã¢ãã
ãã³ç¡«é žå¡©ã溶液ãšããŠç®äžçã«åæè¬ãããã
ãŠäœéKgãããã±ã¿ãã³å¡©é žå¡©100mgããã³ãã·
ã©ãžã³ïŒmgãè ¹è å æäžããŠéº»é ããããã®ç 究
ã§ã¯çŽåŸçŽ13ÎŒïœã®è žéèã®å°åèããã³å°éè
ãè±æ°ããæµåãã©ãã€ã³ã§è¢«èŠããŠäœ¿çšããã
4Wã¢ã«ãŽã³ã¬ãŒã¶ãŒãã¹ãã¯ãã© ãã€ãžãã¯
ã¹ç€ŸïŒSpectra Physicsããã«ã ã·ãŠã¿ããïŒ
補ãã®å æãå éé©å¿èª¿ç¯è£ 眮ãããŒãã€ãŒãžãŒ
瀟ïŒBTG瀟ãããŠãããïŒè£œããçšããŠé¡åŸ®é¡
ãICM405ãLDâãšããã©ã³ãïŒLDâEpiplandïŒ
40ïŒ0.60ïŒãã¢ã€ã¹ïŒZeissïŒç€Ÿè£œãªãŒãã«ã³ã
ãã³ãã®é転å è·¯ã«å軞çã«å°å ¥ããã䜿çšãã
æ³¢é·ã¯514.5nïœã§ããã30.5ïœïŒ·ã®å¯Ÿç©ã¬ã³ãºã
ããé«ããšãã«ã®ãŒãæãããïŒåã®ç §å°ããã
ã®é²å æéã¯1/15ç§ã§ãã€ãããã¹ãŠã®æž¬å®æäœ
ã¯ãããªã«ã¡ã©ïŒããªãã³ã³ããŠãŒãããœããŒç€Ÿ
補ã±ã«ã³ïŒã«èšé²ãããèšé²èšããœããŒç€Ÿè£œãŠãŒ
ããã€ãã¯ïŒïŒµâmaticïŒ3/4â³ãã«ä¿åãããŠã
ããè©Šéšç©è³ªã¯çµå£æäžã®å Žåå®éšéå§ã®ïŒæé
ãŸãã«ããããŠéèå æäžã®å Žåãã®10åãŸãã«
çš®ã ã®æäžéã§å®éšåç©ã«æäžããå¯Ÿç §åç©ã«ã¯
åéã®ãã©ã»ããŒãæäžãããã€ãã®ããã«ããŠ
äžèšã®ç©è³ªãæäžãããããªãã¡(1)åç¬æäžãšã
ãŠ(2)çµåãããšããŠäžç·ã«ã(3)æåã«ã¢ã»ãã«ãµ
ãªãã«é žãããããŠïŒæéåŸã«ãã³ããã·ãã€ãª
ã³ãŸãã¯ä»ã®ããµã³ãã³èªå°äœãããããŠ(4)æå
ã«ãã³ããã·ãã€ãªã³ãŸãã¯ä»ã®ããµã³ãã³èªå°
äœãããããŠïŒæéåŸã«ã¢ã»ãã«ãµãªãã«é žãæ
äžããïŒè¡š1aïŒãè¡š1bã«ã¯çš®ã ã®æéééã®å¹æ
ã瀺ããããè¡š1cã«ã¯ä»ã®ããµã³ãã³èªå°äœã®äœ
çšãèŠçŽãããŠããã è© äŸ¡ äžå®ã®è¡æ ãèªçºããããã«å¿ èŠãªç §å°åæ°ã
æ°ãããããç §å°é »åºŠã¯ïŒåæ¯ã«ïŒåã®ç å€ãç
ããããã«èª¿ç¯ãã芳å¯æéäžã«çæãããæäœ
è¡ç®¡çŽåŸã®1/4ã®å€§ãããæãããã¹ãŠã®è¡æ ã
èšæ°ã枬å®ããã å®éšçµæã¯Ï2ãã¹ãã䜿çšããçµ±èšåæã«ä»ã
ãïœãšã« ã«ããªãŒã¹ã«ã¶æ°èããã€ãªã¡ããª
ãŒããL.Cavalliâsforzaæ°èãBiometrieïŒçç©çµ±
èšåŠïŒãã·ãŠã¿ããã¬ã«ã1969幎çºè¡ã第49é ã
ãã³ãã以éïœã çµ æ çµæã¯è¡š1aãïœã«èšé²ããããã¢ã»ãã«ãµãª
ãã«é žãŸãã¯ãã³ããã·ãã€ãªã³ïŒmgïŒKgã®åç¬
çµå£æäžã«ããäœçšã¯ææã§ã¯ãªããããã³ãã
ã·ãã€ãªã³ã¯è¡æ 圢æã«å¯ŸããŠ20ïŒ ã®æå¶ã瀺
ããäž¡æ¹ã®ç©è³ªã¯10mgïŒKgã®çµå£æäžéã§ææãª
äœçšãæããããã³ããã·ãã€ãªã³ããã³ã¢ã»ã
ã«ãµãªãã«é žã®åææäžã¯äžèšã®ã¬ãŒã¶ãŒã¢ãã«
ã«ãããŠäœçšã瀺ããªãã€ãããã®ããšã¯æåã«
ã¢ã»ãã«ãµãªãã«é žãæäžããïŒæéåŸã«ãã³ã
ãã·ãã€ãªã³ãæäžããå Žåãåæ§ã§ãã€ããã
ããšã¯å¯Ÿç §çã«æåã«ãã³ããã·ãã€ãªã³ããã
ããŠïŒæéåŸã«ã¢ã»ãã«ãµãªãã«é žãæäžããå Ž
åã«ã¯ãã©ããè žéèã®å°åèããã³å°éèã«ã
ããŠã¬ãŒã¶ãŒã§èªçºãããè¡æ çã¢ãã«ã«ãããŠ
æäžéäŸåæ§ã®ææãªäœçšã瀺ããããåç¬æäž
ãšæ¯èŒããŠãã®é 次çæäžã®è¶ éå æçå¹æã¯å¯Ÿ
ç §ãšæ¯èŒããŠå€åã®ããŒã»ã³ããã極ããŠæçœã§
ããïŒè¡š1aïŒã è¡š1bã«èšèŒãããçµæã¯ïŒã€ã®åç¬æäžã®é
ã§éžã¶ããšãã§ããæéçééã«ã¯åºãç¯å²ãã
ãããšã瀺ããã15åãªãã180åãæé©ã§ããã
æ¬çºæã«ããå¹æã¯ä»ã®ããµã³ãã³èªå°äœïŒç¹èš±
è«æ±ã®ç¯å²åç §ïŒãçšããŠãéæããããšãã§
ãããã®å Žåã«ã¯ãããã¯ã¢ã»ãã«ãµãªãã«é žãš
ãšãã«æäžããããããã ãéœåã®ããæéã«æ
ãå€ããŠæäžãããããããã®ããµã³ãã³èªå°äœ
ã®éžæã«é¢ããæè¡æ 圢æäœçšã¯è¡š1cã«èšé²ãã
ãŠããã ãã®é 次çæäžã¯ïŒã€ã®å¥ã ã«å¶åŸ¡ã§ããéšå±
ãæããåæ¥äžå ¥æå¯èœãªçæµè£ 眮ãããšãã°ã
ã©ãŠã³ç€ŸïŒBraunãã¡ã«ã¹ã³ã²ã³ïŒã«ããäŸçµŠã
ãããã®ãã¿ã€ã ã¹ã€ããã«ããåé¢ããããã«
èæ¡ãããã¢ãŒã¿ãŒé§åäŸçµŠåšãè£ åããŠããã
ã䜿çšããŠè¡ãããšãã§ããããã®çæµè£ 眮ã®ïŒ
ã€ã®éšå±ã¯ãããããã³ããã·ãã€ãªã³æº¶æ¶²ïŒã©
ããKgããããã³ããã·ãã€ãªã³10mgã«çžåœã
ãïŒããã³ã¢ã»ãã«ãµãªãã«é žæº¶æ¶²ïŒKgãããïŒ
mgã«çžåœããïŒïŒæº¶åªã«å¯ŸããŠã¯äžèšåç §ïŒã§æº
ãããããå°Ÿéèã«ãã³ããã·ãã€ãªã³æº¶æ¶²ã泚
å°ããŠ20ååŸã«ã¢ã»ãã«ãµããªã«é žæº¶æ¶²ã泚å°ã
ãããã«ã¿ã€ã ã¹ã€ããã«ããå¶åŸ¡ãããæ¯èŒå®
éšã«ãããŠã¯äž¡æ¹ã®éšå±ã®æ¶²ãåæã«æ³šå°ããã
çµæã¯çµå£æäžåŸã«åŸããã枬å®å€ã«çžå¿ããŠã
ããããªãã¡é 次çæäžã«ãããŠåŸãããäœçšã¯
åææäžã«ãããŠåŸãããäœçšãããã¯ããã«å€§
ããã€ãã çäœå€ã§ã®ç 究 æ¬æ¥æ¢ç¥ã®æ¹æ³ã«ããè¡å°æ¿åéã枬å®ããã
éæ§å®¶å ïŒèªå®¶é£Œè²ãBASKãSPFãŠã€ã¬ç³»ãçŽ
2.5ã3.5KgïŒãççé£å¡©æ°Žã«æº¶è§£ãããã³ããã·
ãã€ãªã³ããã³ïŒãŸãã¯DLâãªãžã³ã¢ãã¢ã»ã
ã«ãµãªã·ã¬ãŒãã§éèå ïŒè³ã®éèïŒçã®åŠçã
ããã€ãã«è³éèããæ¡è¡ãã3.8ïŒ ãããé žäž
ãããªã ãŠå¡©ã®æº¶æ¶²ãïŒïŒïŒã®å²åã§å ãããã
ãŠãã®æ··åç©ã宀枩ã§45åéã€ã³ããŠããŒãã
ããã€ãã«ãããïŒåéããã1000å転ã§10åé
é å¿åé¢ãããè¡å°æ¿ã«å¯ãè¡æŒ¿ãå«ãäžå±€ãå
é¢ãããããŠäžå±€ãïŒåéããã28000å転ã§10
åéé å¿åé¢ãããåæ§ã«åé¢ããäžå±€ã¯ä»åºŠã¯
è¡å°æ¿ã«ä¹ããè¡æŒ¿ãå«æããŠãããè¡å°æ¿ã«å¯
ãè¡æŒ¿ãïŒmlãããè¡å°æ¿çŽïŒãïŒÃ108åãå«
ãããã«è¡å°æ¿ã«ä¹ããè¡æŒ¿ã§åžéãããã³ãŒã«
ã¿ãŒã«ãŠã³ã¿ãŒãã³ãŒã«ã¿ãŒãšã¬ã¯ãããã¯ã¹ç€Ÿ
補ã¯ã¬ããšã«ãïŒCoulter counterãCoulter
ElectronicsãKrefeldïŒããè¡å°æ¿ã®åéã¯ããŒã³
ïŒBornïŒåéæ€åºèšãã¬ãŒããŒïŒLaborïŒGmbH
補ããã³ãã«ã°ããçšããŠå ã®ééã枬å®ããã
ãšã«ããå åŠçã«è¿œè·¡ãããè©Šéšæ··åç©ã®å®¹éã¯
0.25mlã§ããããããŠæž©åºŠã¯37âã§ãã€ããä¿è·
æ°äœïŒã¢ã«ãŽã³ïŒäžã§ã®ãã¬ãã©ãã€ãé«é液äœ
ã¯ãããã°ã©ãã€ãŒïŒHPLCéçžïŒ£â18ã«ã©ã ïŒ
ã«ãã粟補ããã¢ã©ããã³é žããµãŒã瀟
ïŒServaããã€ãã«ãã«ã°ïŒãïŒÃ10-4MãçšããŠ
åéãåŒãèµ·ããããè¡å°æ¿åéã®å¢å€§ã¯å ã®é
éã«åºã¥ããŠè¿œè·¡ããããã®ç³»ã§æž¬å®ãããå€æ°
ã¯æ倧åéæ¯å¹ ã§ãããçµæã¯è¡šïŒã«èšé²ãã
ãã éæ§ã©ãããããšãŠã€ã¹ã¯ãç³»ïŒHoe
WiskfïŒãçŽ180ïœããã€ãã®è¬ç©ãããªãšãã¬ã³
ã°ãªã³ãŒã«ïŒPEGãååé400ïŒäžãKgãããïŒ
mlã«çžåœãã®çµå£æäžã«ããåŠçããã å®éš(1) ãã³ããã·ãã€ãªã³30mgïŒKgã30ååŸã«
ã¢ã»ãã«ãµãªãã«é žïŒmgïŒKgã å®éš(2) ãã³ããã·ãã€ãªã³30mgïŒKgã30ååŸã«
ã¢ã»ãã«ãµãªãã«é ž10mgïŒKgã å®éš(3) ã¢ã»ãã«ãµãªãã«é ž30mgïŒKgã30ååŸã«
ãã³ããã·ãã€ãªã³30mgïŒKgã å®éš(4) ã¢ã»ãã«ãµãªãã«é ž10mgïŒKgã30ååŸã«
ãã³ããã·ãã€ãªã³30mgïŒKgã å®éš(5) ãã³ããã·ãã€ãªã³30mgïŒKgã30ååŸã«
溶åªã®ã¿ã å¯Ÿç §å®éš(6) è¬ç©ãçšããã«PEG400 ïŒmgïŒKgã ãããã®æäœã18æéåŸã«ããè¿ããæåŸã«æ
äžããŠïŒæéåŸã«ãšãŒãã«éº»é äžã§ã©ãããç ç²
ã«ãããããŠèžå€§åèãé€å»ããã倧åèã®ã»ã°
ã¡ã³ãïŒåç¯ïŒããã ã¡ã«ç·©è¡åããã0.09Må¡©
åãããªãŠã 溶液ïŒPH7.5ïŒïŒmläž24âã§30åé
ã€ã³ããŠããŒããããã€ãã«å€§åèããã®äžæŸã¿
液ã®äžå®éãã€ãã®ããã«ããŠã¢ããã·ã³äºçé ž
ã§èªçºããã人è¡å°æ¿ã®åéã«å¯Ÿããé»å®³å€ãšã
ãŠäœ¿çšãããããªãã¡10æ¥éè¬ç©ããšããªãã€
ããå€èŠäžå¥åº·ãªç·æ§ããã³å¥³æ§ã®å¿é¡è ããå
è åéšã®éèã«æ³šææ·±ãã«ããŠãŒã¬ãæ¿å ¥ããŠæ¡
è¡ãããããŠãã ã¡ã«ãããé žãããªãŠã ïŒ0.38
ïŒ å ããïŒã§æ» èãããè¡å°æ¿ã«å¯ãè¡æŒ¿
ïŒPRPïŒã¯140Ãïœã§15åéé å¿åé¢ããã®ã¡ã«
äžæŸã¿æ¶²ãšããŠåŸãããããã®è¡å°æ¿å«éã¯2.5
ã3.5Ã108ïŒmlã®ç¯å²å ã§ãã€ãïŒã¯ãŒã«ã¿ãŒã«
ãŠã³ã¿ãŒïŒãè¡å°æ¿ã®åéã¯ããŒã³åéæ€åºèš
ïŒã¬ãŒããŒGmbH補ããã³ãã«ã°ïŒãçšããŠå ã®
ééã枬å®ããããšã«ããå åŠçã«è¿œè·¡ãããè©Š
éšæ··åç©ã®ç·éã¯0.25mlã§ãã€ããè¡æŒ¿ãäžèšã®
倧åèäžæŸã¿æ¶²ãšãšãã«37âã§ïŒåéãã¬ã€ã³ã
ãŠããŒãããã€ãã§ïŒÃ10-6Mã¢ããã·ã³äºçé ž
ãçšããŠåéãèªçºãããããããã®å Žåã«æ倧
åéæ¯å¹ ãã倧åèã®ééãé¢æ°ãšããæäžéâ
äœçšæ²ç·ãäœæãããããã®ã°ã©ããã倧åè
0.1mgããåŸãããäžæŸã¿æ¶²ã«ãããæåé掻æ§
ã決å®ããã倧åèã®ééã¯60âã§20æé也ç¥ã
ã倧åèã秀éããããšã«ãã枬å®ãããæ¡è¡åŸ
ïŒãïŒæé以å ã«åé枬å®ãè¡ã€ãã æ¯æ§è©Šéšæ¹æ³ïŒ äžèšãšåæ§ã«ããŠã©ãããçµå£çã«åŠçãã
ãããã ãæäžéãå¢å ããªããè¡ã€ããäžçŸ€ã«
ã¯ãã³ããã·ãã€ãªã³ãæäžãããããŠç¬¬äºã®çŸ€
ã«ã¯ãã³ããã·ãªã³ãã©ã¹ã¢ã»ãã«ãµãªãã«é žã
10ïŒïŒã®ééæ¯ã§æäžãããéåžžã®æšæºçæ¹æ³
ããªãããã€ãŒã«ãããã³ãŠã€ã«ã³ããœã³äž¡æ°
ïŒLitchfieldããã³WilcoxonïŒã1949幎ïŒã«ãã
LD50ãšããŠèŽæ»éãèšç®ããã LD50ïŒãã³ããã·ãã€ãªã³ïŒïŒ1400mgïŒKg LD50ïŒãã³ããã·ãã€ãªã³ïŒã¢ã»ãã«ãµãªãã«
é žïŒ ïŒ1400mgïŒKg çµ æ æ¯ç©åŠç蚱容æ§ã¯äž¡çŸ€ãšãåæ§ã§ãã€ãããã®
ããšã¯æ¬çºæã«ãããã³ããã·ãã€ãªã³ããã³ã¢
ã»ãã«ãµãªãã«é žãšã®çµåããã«å¯ŸããŠè¬åŠçæ
äžéããã³èŽæ»éãšã®æ¯ãã¯ããã«å°ããããšã
æå³ããŠãããåŸã€ãŠãã³ããã·ãã€ãªã³ãŸãã¯
ã¢ã»ãã«ãµãªãã«é žãåç¬ã§æäžããå Žåããã
ããªã奜éœåã§ããã èã®èš±å®¹æ§è©Šéš æ¹ æ³ äœé200ã300ïœã®çµ¶é£ããéæ§ã¹ãã¬ã€ã°ããŠ
ã¬ã€ç³»ã©ãããäžèšãšåæ§ã«ããŠãã³ããã·ãã€
ãªã³ã§ããã®ïŒæéåŸã«ã¢ã»ãã«ãµãªãã«é žã§çµ
å£çã«åŠçãããããŸãã¯ã¢ã»ãã«ãµãªãã«é žã
ãã§çµå£çã«åŠçãããæåŸã«è¬ç©ãæäžããŠ24
æéåŸã«å°åœã«æ²¿ã€ãŠèãåéããæµæ°Žã§æž æµã«
ãããããŠç²èã®ç å€ãæ€æ»ãããèçŒçæ€æ»ã§
æ€åºãããè ºå§èç²èã®ãã¹ãŠã®ç å€ã¯æœ°çãšã¿
ãªããã çµ æ ã¢ã»ãã«ãµãªãã«é žã®è朰çèªçºæ§ã¯ãã³ãã
ã·ãã€ãªã³ã§ååŠçããããšã«ãã圱é¿ãåããª
ãïŒè¡šïŒïŒããã®ããšã¯æ¬çºæã«ããçµåãã
ïŒã¢ã»ãã«ãµãªãã«é žã®ãŸãã«ãã³ããã·ãã€ãª
ã³ãæäžããïŒã®å Žåãèã蚱容ã§ããªããããª
æäžéã«å¯Ÿããè¬åŠçæäžéã®æ¯ããã¢ã»ãã«ãµ
ãªãã«é žã®åç¬ã§æäžããå Žåãããããªãå°ã
ããããæå©ã§ããããšãæå³ããããªããªãã°
è¡šïŒã«ããã°åŸè ã®å Žååäžã®æè¡æ 圢æäœçšã
åŸãããã«ã¯ããªã倧éã®ã¢ã»ãã«ãµãªãã«é žã
å¿ èŠãšããããã§ããã æ ¢æ§çççã®ã¢ãã«ã䜿çšããç 究 æ¬çºæã«ããçµåããã®è¡æµåŠçäœçšãæè¡æ
圢æäœçšãæåéäœçšããã³æççäœçšã¯ãã¯ãª
ãã«ã« ãã¢ã«ããªããžãŒãïŒãClinical
HemorheologyãïŒç¬¬ïŒå·»ç¬¬469ã480é ïŒ1983幎ïŒ
ã®æ¹æ³ã«ãããã©ããã¢ãžãŠãã³ãé¢ç¯çã®ç ç
åŠçã¢ãã«ããã³ãã¯ããªãŠã ãããªã¯ã
ïŒMycobacterium butyricumïŒãçšããŠåŒãèµ·
ãããã«ãããŠ21æ¥éçµå£æäžããã®ã¡æ€æ»ãã
ãããŠé©åœãªåã ã®ç©è³ªã®ãã®ãããªäœçšãšæ¯èŒ
ãããç©è³ªã®æåŸã«æäžããŠïŒæéåŸã«èžå€§åè
ããæ¡è¡ãããè¡æµåŠçäœçšã«é¢ãã枬å®ã®è©³çŽ°
ã¯ãã¹ãŠãã¯ãªãã«ã« ãã¢ã«ããªããžãŒã
ïŒãClinical HemorheologyãïŒç¬¬ïŒå·»ç¬¬263ã273
é ïŒ1984幎ïŒã«èšèŒãããããã«ããŠè¡ã€ããèµ€
è¡çå€åœ¢å¯èœæ§ã¯æµãæ²ç·ã®åæåŸé ãè©äŸ¡ãã
ããšã«ãããã€ã«ããã¡ãŒã¿ããã¬ã³MF4
ïŒMyrenne MF4ãã¬ãŒãã²ã³ç€Ÿãã€ãïŒãçšã
ãŠå®éçã«è©äŸ¡ãããå¥åº·ãªå¯Ÿç §ã©ãããšæ¯èŒã
ãŠé¢ç¯çã©ããã«ãããŠäœäžããŠããèµ€è¡çã®
éæ§ã¯ã¢ã»ãã«ãµãªãã«é žããã³ãã³ããã·ãã€
ãªã³ã«ããåã³å¢å€§ã§ããããšãè¡š5aã«ç€ºãã
ããäžèšïŒçš®ã®ç©è³ªãçµåãããŠåæã«æäžãã
å Žåã§ããè¶ éå æçå¹æã瀺ãããé 次çæäž
ïŒã¢ã»ãã«ãµãªãã«é žã®ïŒæéãŸãã«ãã³ããã·
ãã€ãªã³ãæäžïŒã®å Žåãããã®å¹æã¯ç¹ã«é¡è
ã§ããã äžèšãšåæ§ã®ã¬ãŒã¶ãŒã¢ãã«ã䜿çšããŠæè¡æ
圢æäœçšã枬å®ãããè¡š5bã«ã¯çµæã瀺ãããã
å¥åº·ãªå¯Ÿç §åç©ã«ãããŠè¡æ ã圢æããããã«ã¯
å¹³å2.173ïŒïŒ100ïŒ ïŒã®ã¬ãŒã¶ãŒç §å°ã䜿çšããª
ããã°ãªããªãããé¢ç¯çã«æ£ã€ãåç©ã®å Žåã¯
0.99ïŒïŒ46ïŒ ïŒã®ç §å°ã§å åã§ãããããªãã¡è¡
æ çã®åŸåã¯ç æ°ã«ããã€ãåç©ã«ãããŠå¢å€§ã
ãŠãããè¡æ çã®çµå£ã¯è¬ç©ã§æ²»çããããšã«ã
ããç¹ã«æ¬çºæã«ããçµåããå€ãæäžããããš
ã«ããæžå°ããå¥åº·ãªåç©ã«å¯ŸããŠèŠãåºããã
å³ãšè¿äŒŒããŠããããšãè¡š5bã«ç€ºãããã è¡å°æ¿åéã«é¢ãã枬å®ã¯äžèšã«è©³è¿°ãããã
ãã«ããŠè¡ããããããããªããè¡å°æ¿ã«å¯ãè¡
挿ïŒmläžã§è¡å°æ¿ã®åéãåŒãèµ·ããããã«ã¢ã©
ããã³é žã®ä»£ããã«ã³ã©ãŒã²ã³0.04mgã䜿çšãã
ããã¬ã³ç€Ÿè£œPAååéæ€åºèšïŒMyrenneãã¬
ãŒãã²ã³ïŒããåéæ¯å¹ ïŒåéåŸåïŒã¯ç¡åŠçã®é¢
ç¯çã©ããã®å Žåã«æãé«ããïŒïŒ100ïŒ ïŒãå¥åº·
ãªã©ããã«ãããŠ0.04mgã®ã³ã©ãŒã²ã³ãçšããŠã
åéã¯çèµ·ããªãïŒè¡š5cïŒãèšèŒããçµæã¯é¢ç¯
çã©ããã«ãããŠç çåŠçã«å¢å€§ããåéåŸåã¯
äžèšã®è¬ç©ã«ããäœæžã§ããããšã瀺ããŠããã
é 次çæäžïŒãã³ããã·ãã€ãªã³ããããŠïŒæé
åŸã«ã¢ã»ãã«ãµãªãã«é žïŒã¯ãã®å Žåãè¶ éå æ
çå¹æã瀺ãã æççäœçšã¯äžèšã«åŒçšããããã«ããŠæµ®è «ã
æããè¢ã®äœç©ããã³æšæºçãªå£æ»ææ°ã䜿çšã
ãŠå®éçã«æž¬å®ãããå£æ»ããã³æµ®è «ã®çæã¯äž
èšã®è¬ç©æ²»çã«ããé¡èã«æžå°ãããåŠçãããŠ
ããªãé¢ç¯çã©ãããšæ¯èŒããŠåŠçãããåç©ã®
çç¶ã«ãããçžå¯Ÿçãªæ¹åãè¡šïŒã«ç€ºããããã
ã®å Žåãæ¬çºæã«ããé 次çæäžïŒãã³ããã·ã
ã€ãªã³ããããŠïŒæéåŸã«ã¢ã»ãã«ãµãªãã«é žïŒ
ã¯è¶ éå æçå¹æã瀺ãã è¬åŠçåŠæ¹ç© äžèšã®çæµè£ 眮ã«ããéèå 泚å°ã®ä»£ããã«ã
è¶ éå æçå¹æãéæããããã«çµå£ããã³çŽè ž
æäžã«é©åœã§ããæžæ¿ç©ããã³åºäœç¶åŠæ¹ç©ã䜿
çšããããšãã§ããã 人ã«æäžããããã®ãã®çš®ã®åŠæ¹ç©ã®äŸã¯ã¢ã»
ãã«ãµãªãã«é žïœmgãšçµåãããŠçŽç²ãªç©è³ªãšã
ãŠãã³ããã·ãã€ãªã³ãŸãã¯ä»ã®ããµã³ãã³èªå°
äœïŒå®æœäŸïŒã17åç §ïŒïœmgããã³ïŒãŸãã¯åæ¥
äžå ¥æå¯èœãªæçµåŠæ¹ç©ãã¢ã«ããŒã ã«ãŒã»ã«
ãã¢ãŒãGmbHããäŸçµŠããããã¬ã³ã¿ã«(R)
ïŒTrental(R)ãAlbert Roussel Pharma GmbH
ïŒãŠã€ãŒãºããŒãã³ïŒããäŸçµŠïŒãŸãã¯Dr.ã¬ã³ã
ãšã©ãŒã¢ã«ããã€ãããã«GmbHããäŸçµŠãã
ãã¬ã³ããªã³(R)ïŒRentylin(R)ãDrãRentschler
Arzneimittel GmbHïŒCo.ïŒã©ãŠããšã€ã ïŒãã
äŸçµŠïŒãïŒããããããã³ïŒ²ãšç¥ãïŒããŸãã¯ã
ããã®æçµåŠæ¹ç©ã®äžéšãå«æããããã®å Žåã¢
ã»ãã«ãµãªãã«é žãŸãã¯å¡©åºæ§ã€ãªã³äº€æäœïŒã
ãŠãšãã¯ã¹(R)ïŒÃïŒãããã³QAEâã»ãã¢ãã
ã¯ã¹(R)ïŒDowex(R)ããã³QAEâSephadex(R)ããµ
ãŒã瀟ïŒServaïŒãã€ãã«ãã«ã°ïŒããŸãã¯åžç
æš¹èãã¢ã³ããŒã©ã€ã(R) XAD2ïŒAmberlite(R)ïŒã
ãšçµåãããããšãã§ãããŸãåæ¥çã«å ¥æå¯èœ
ãªãã€ã¯ãã«ãã»ã«ãã³ã«ãã¢ãªãã(R)ããã€ã€
ãŒAG瀟ïŒColfarit(R)ãBayer AGïŒã¬ããŒã¯ã»
ã³ïŒãïŒïŒ£ãšç¥ãïŒãŸãã¯çµæ¶ãããŒã ãã¢ãŒã
GmbHããäŸçµŠãããR95Dããã³M80DïŒRohm
Pharma GmbHããã€ã¿ãŒã·ãŠã¿ããããã€
ãïŒãã®åœ¢æ ã§ãã€ãŠãããããããã®çµåãã
å€äžã®è¬åŠç賊圢å€ã¯å ç±ã«ããåºåããã²ã«ã§
ããïŒããªãã¡(a)æ°ŽäžãŒã©ãã³20ééïŒ ïŒã°ãªã»
ãªã³ïŒééïŒ ã(b)æ°Žäžã¢ã¬ããŒã¹ïŒééïŒ ããã
ã³(c)ã¢ã»ãã³ïŒæ°ŽïŒ80ïŒ20ééïŒ ïŒäžãšãã«ã»ã«
ããŒã¹T50ïŒãã«ã¯ã¬ã¹GmbHããã³ãã«ã°ïŒ10
ééïŒ ã§ãããããããã®å Žåã«ïŒééïŒ ã®ãã³
ããã·ãã€ãªã³ãŸãã¯ä»ã®ããµã³ãã³èªå°äœãæ¹
æäžã§å ããããŠãããããŸãã¯å ããããŠããª
ãïŒãããŸãã¯åæ¥äžå ¥æå¯èœãªãŒã©ãã³ã«ãã»
ã«ïŒäººããã³å€§ããåç©ã«æäžããããããµã€ãº
ïŒïŒã«ãã¹ã²ã«ç€ŸïŒKapsugelãããŒãŒã«ïŒã«ã
ãäŸçµŠïŒã§ããã ç¬ã®è液10mlãŸãã¯0.1Nå¡©é ž10mlã«äžèšã®è¬
åŠçåŠæ¹ç©ïŒå®æœäŸïŒã17åç §ïŒãå ãããããŠ
è©Šéšç®¡å ã§ç©åã«æ¹æããªãã37âã§ä¿æããã
äžæŸã¿æ¶²ã®äžå®éãç¹å®ã®æéééã§æãåãã
é«é液äœã¯ãããã°ã©ãã€ãŒãã«ã©ã ïŒã©ãã
ããã¯C18ãŠãªãŒã¿ãŒãºGmbHãšã·ãŠããŒã³ãã
ã€ãïŒRad Pak C18ãWaters GmbHïŒ100ÃïŒ
mmã10ÎŒïœã移åçžïŒã¡ã¿ããŒã«300mlïŒé ¢é žïŒ
mlãæ°Ž700mlãæµé1.5mlïŒåãã«ããåå¥ããã
ããã®æåã280nïœã«ãããUVæ€åºã«ããå®é
çã«æž¬å®ããããã®è¬åŠçåŠæ¹ç©ã¯åäºæè žæ¶²
ïŒç¬ïŒã«ããŸãã¯çé žæ°ŽçŽ ãããªãŠã 液ïŒPH7.4ïŒ
ã«åæ§ã®æ¹æ³ã§å ããããã å°åç©ã«æäžããããã«ã¯ïŒè¡šïŒã®ã©ãããå
ç §ïŒãå®æœäŸïŒã17ã«èšèŒãããåŠæ¹ç©ã®æåã
ãããã1/200ã®ééã«æžãããããŸãã¯ãµã€ãº
ïŒããã³ïŒã®ã«ãã»ã«ã䜿çšããã
ããµã³ãã³ïŒãã³ããã·ãã€ãªã³ïŒã¯è¡æ¶²ã®æµã
æ§è³ªãæ¹åããããã®è¬å€ãšããŠäœ¿çšãããããš
ãç¥ãããŠããããã®ããšã®æšå®ãããçç±ã¯
ãããã€ããš ã¡ãã€ã ããªãã³ã·ãŠãªããã
ïŒDeutsche Mediz.WochenschriftïŒç¬¬107巻第
1674é ïŒ1982幎ïŒããã³ããã·ãã€ãªã³ã§åŠçœ®ã
ãããšã«ããèµ€è¡çã®å€åœ¢å¯èœæ§ãæ¹åãããã®
ã§ãè¡æ¶²ã®ç²åºŠæµæãæžå°ãããšããããšã«ã
ããããã«è©Šéšç®¡å ã§è¡å°æ¿ã®åéããã³ããã·
ãã€ãªã³ã«ããæå¶ããããšã¯ã§ãããããã ã
ãã®ããšã¯å»åŠçæ²»çã§äœ¿çšããããããé«ãæ¿
床ã§ã®ã¿å¯èœã§ãããïœã¢ã€ã¢ãŒã«ã·ãŒãšã¹ïŒã¡
ãã ãµã€ïŒãIRCSïŒMed.Sci.ïŒã第ïŒå·»ç¬¬293é
ïŒ1980幎ïŒããããã³ãã¹ãã¢ã¹ã¿ã¹ã
ïŒãThrombos.Haemostas.ãïŒç¬¬46巻第272é
ïŒ1981幎ïŒïœã ããã«ãã³ããã·ãã€ãªã³ã«é¢ããŠã¯ãçäœå€
ã§ã®ã©ãã倧åèããã®æåé掻æ§ãæããç©è³ª
ã®æŸåºã¯ãã®åç©ããã³ããã·ãã€ãªã³ã§åŠçã
ãããšã«ããå¢å€§ã§ããããšãå ±åãããŠããã
åæ§ã«ãŸãæåé掻æ§ãæããç©è³ªã®æŸåºããã
ããããã¯åºæ¿ãããããšã«ããããã¹ã¿ãµã€ã¯
ãªã³ã®æŸåºã§ããããã©ãããã¢ã»ãã«ãµãªãã«
é žã§åŠçããããšã«ããæå¶ã§ããããšãç¥ãã
ãŠãããããµïŒãVasaãïŒç¬¬10巻第249é ïŒ1981
幎ïŒãã âã¢ã»ãã«ãµãªãã«é žã¯äººã®è¡å°æ¿åéé»å®³
å€ã§ããããšãç¥ãããŠãããããšãã°ããã«
ãžãšã€ ã¯ãªã³ ãã¢ãŒããã¯ãïŒãBr.J.Clin.
Pharmac.ãïŒç¬¬ïŒå·»ç¬¬283é ïŒ1979幎ïŒãããããŠ
ããã¯è¡æ çããã³çºäœãé»æ¢ããããšã«ããé
èŠãªæ²»çå¹æãçºæ®ã§ããããšãå ±åãããŠãã
ãããã©ãããïŒãBloodãïŒç¬¬52巻第1073é ïŒ1978
幎ïŒãããšã ã€ã³ã°ã« ãžãšã€ ã¡ãããïŒãN.
Engl.J.Med.ãïŒç¬¬299巻第53é ïŒ1978幎ïŒãããã®
äœçšæ©æ§ã¯ã¢ã»ãã«ãµãªãã«é žãè¡å°æ¿äžã«å±åš
ããé µçŽ ã·ã¯ããªãã·ã²ããŒãŒãé»å®³ããããžãš
〠ã¯ãªã³ ã€ã³ãã¹ããïŒãJ.Clin.Invest.ãïŒç¬¬
56巻第624é ïŒ1975幎ïŒãããããŠåéãä¿é²ãã
ããã³ãããµã³A2ã®çåæãæå¶ããããšã§ã
ããšå ±åãããŠãããããããªããã¢ã»ãã«ãµãª
ãã«é žã¯ãŸãè¡ç®¡å£ã«å±åšããã·ã¯ããªãã·ã²ã
ãŒãŒãé»å®³ããããšãã§ããåŸã€ãŠåéãé»å®³ã
ãããã¹ã¿ãµã€ã¯ãªã³ã®åæãé»å®³ããããšãã§
ãããããããªããè¡ç®¡ã®ã·ã¯ããªãã·ã²ããŒãŒ
ã®é»å®³ã¯é«æäžéã®ã¢ã»ãã«ãµãªãã«é žã«ãããŠ
ã®ã¿èªãããããããã¢ãŒãã³ã ãªãµãŒã ã³
ã³ããŠãŒã³ãïŒãPharmacol.Research
Commun.ãïŒç¬¬10巻第759é ïŒ1978幎ïŒãã®ã§ãåŸ
ã€ãŠæè¡æ 圢æäœçšãäœæäžéã®ã¢ã»ãã«ãµãªã
ã«é žãçšããŠéæããããšããããšãæšå¥šããã
ããã©ã³ã»ãããïŒãLancetãïŒç¬¬å·»ç¬¬1213é
ïŒ1979幎ïŒããããã¹ã¿ã°ã©ã³ãžã³ãº ã¢ã³ã ã¡
ãã€ã¹ã³ãïŒãProstaglandins and MedicineãïŒ
第ïŒå·»ç¬¬439é ïŒ1980幎ïŒããããããªãããŸãã¢
ã»ãã«ãµãªãã«é žã®æè¡æ 圢æäœçšã¯æäžéã®å¢
倧ãšãšãã«å¢å€§ããããã¹ã¿ãµã€ã¯ãªã³ããã³ã
ãã³ãããµã³ã®äž¡æ¹ã®çåæãå®è³ªçã«é»å®³ãã
ãããªæ¡ä»¶äžã§æ倧ã®å¹æãéæã§ãããšããå ±
åãããããããã¹ã¿ã°ã©ã³ãžã³ãº ãã€ã³ããª
ãšã³ãº ã¢ã³ã ã¡ãã€ã¹ã³ãïŒãProstaglandins
Leukotrienes and MedicineãïŒç¬¬12巻第235é
ïŒ1983幎ïŒãã äžæ¹ã§ã¯ã¢ã»ãã«ãµãªãã«é žã®ããããŠä»æ¹ã§
ã¯ããµã³ãã³èªå°äœã§ããïŒâïŒïŒâãžãšãã«ã¢
ãããšãã«ïŒããªãã€ãªã³ã®æå©ãªäœçšãããã
ãïŒçš®ã®åã ã®ç©è³ªã®é žâå¡©åºä»å äœã補é ãã
ããšã«ããäžç·ã«åããããããŠå»åŠã«ãããŠäœ¿
çšããããšããã§ã«é瀺ãããŠããïŒè±åœå ¬éç¹
èš±åºé¡ç¬¬2096138å·æ现æžïŒãããã«ãã³ããã·ã
ã€ãªã³ããã³ã¢ã»ãã«ãµãªãã«é žãçµã¿åãããŠ
åæã«æäžããå Žåã®ã人工å¿èåŒãæããæ£è
ã®è¡å°æ¿çåæéã«åãŒãäœçšãé瀺ãããŠãã
ããã·ã³ã¬ããŒã« ã¡ãã ãžã€ãŒãã«ã
ïŒãSingapore Med.Journalã第20å·»è£éºïŒç¬¬30é
ïŒ1979幎ïŒãã ä»ãã(A)äžæ¹ã§ããµã³ãã³èªå°äœãŸãã¯ããã
ã®æŽ»æ§ä»£è¬ç©ãããããŠ(B)ä»æ¹ã§ã¢ã»ãã«ãµãªã
ã«é žãŸãã¯ãã®è¬çåŠçã«èš±å®¹ãããå¡©ãäžå®ã®
æéçééã§ç¹å®ã®é åºã§é 次ã«æäžããããšã«
ãããé害ã®ããè¡æ¶²æåç¹ã«è¡å°æ¿ãŸãã¯èµ€è¡
çã«ãããããããŠãŸãçœè¡çã«ãããé害ã«ã
ãåŒãèµ·ããããé害ãŸãã¯ãããç¹åŸŽãšããé
害ã®æ²»çã極ããŠå€§ããæ¹åã§ããããšãèŠãåº
ããããé 次çæäžããªãã¡ããµã³ãã³èªå°äœç¹
ã«ãã³ããã·ãã€ãªã³ãæäžããã€ãã§10åéãª
ããïŒæéçµéããã®ã¡ã«ã¢ã»ãã«ãµãªãã«é žãŸ
ãã¯ãã®å¡©ãæäžããããšã«ããããããïŒçš®ã®
ããããã®ç©è³ªãçµåãããŠåæã«æäžããå Žå
ãããã¯ããã«å€§ããäœçšãåŸãããå®éã«åŸè
ã®å Žåã«ã¯ãã®äœçšãäœæžãããããµã³ãã³èªå°
äœããšãã°ãã³ããã·ãã€ãªã³ããã³ã¢ã»ãã«ãµ
ãªãã«é žãåæã«æäžããå Žåã«ã¯ã¢ã»ãã«ãµãª
ãã«é žãåç¬ã§æäžããå Žåã«åŸãããã®ãšåçš
床ã®æè¡æ 圢æäœçšããã³æåéäœçšãåŸããã
ã ãã§ããã®ã§ããã®ããšã¯å šãé©ãã¹ãããšã§
ããïŒä»¥äžã®è¡šïŒããã³ïŒãåç §ïŒã åŸã€ãŠæ¬çºæã¯(A)åŒïŒïŒãŸãã¯ïŒïŒïŒç¹èš±
è«æ±ã®ç¯å²ïŒãåç §ïŒã®ããµã³ãã³èªå°äœãŸãã¯
ãªããœã¢ã«ãã«âãŸãã¯ããããã·ã¢ã«ãã«ããµ
ã³ãã³ã®ãããã©ãã°ãŸãã¯ãããã®æŽ»æ§ä»£è¬
ç©ãããã³(B)âã¢ã»ãã«ãµãªãã«é žãŸãã¯ãã®
è¬çåŠçã«èš±å®¹ãããå¡©ã(C)è¬åŠç賊圢å€ãšãšã
ã«ããŸãã¯ããã䌎ããã«å«æããè¡æ¶²æåç¹ã«
è¡å°æ¿ãŸãã¯èµ€è¡çã ãã§ãªãããŸãçœè¡çã®æ
å·ã«ããåŒãèµ·ããããé害ãŸãã¯ãããç¹åŸŽãš
ããé害ãæ²»çããéã«ãæå(A)ãæåã«æŸåºã
ãããããªæ¹æ³ã§é 次ã«æäžããããã®çµåãã
çæç©ã«é¢ãããæèšããã°ãæ¬çºæã«ããè¬å€
ã¯ãããã®è¶ éå æçäœçšïŒsuperadditive
effectïŒã®ããã«æè¡æ 圢æãè¡æµä¿é²ãæç
çãé®çãæåéããã³çŽ°èå¢æ®æå¶ã®ããã®æ²»
çãŸãã¯äºé²ã«é©åœã§ãããåŸã€ãŠæ¬çºæã¯ãŸã
è¡æ¶²æåã®æå·ã«ããåŒãèµ·ããããé害ã®ãã
ã«ã(A)åŒãŸãã¯ã®ããµã³ãã³èªå°äœãŸãã¯åŒ
ããã³ã®ãªããœã¢ã«ãã«ããµã³ãã³ãŸãã¯åŒ
ã®ããããã·ã¢ã«ãã«ããµã³ãã³ã®ãããã©ã
ã°ã®åœ¢æ ããŸãã¯ãããã®ä»£è¬ç©ãããã³(B)â
ã¢ã»ãã«ãµãªãã«é žãŸãã¯ãã®è¬çåŠçã«èš±å®¹ã
ããå¡©ãã(C)é 次çã«æŸåºãããããªè¬å€ã補é
ããããã®è¬åŠç賊圢å€ãšãšãã«ããŸãã¯ããã
䌎ããã«ãæåãæåã«æŸåºãããããªæ¹æ³ã§
䜿çšããããšã«é¢ãããããã«æ¬çºæã¯ç¹èš±è«æ±
ã®ç¯å²ç¬¬ïŒé ã«èšèŒããããããªè¬åŠçåŠæ¹ç©ã®
補é ããã³äººå»åŠããã³ç£å»åŠã«ããããã®è¬å€
ã®äœ¿çšã«é¢ãããæ¬çºæã«ããçµåããçæç©ã¯
ã¢ã»ãã«ãµãªãã«é žãæŸåºããåã§ããããããµ
ã³ãã³èªå°äœãæŸåºããããããããšããããªã
ã¡çç©åŠçã«å©çšã§ããããã«ããããšãå¯èœã«
ããã ç¹ã«æå©ã§ããããšã¯é 次çã«æäžããããšã«
ããè¶ éå æçå¹æãåŸãããã®ã§ãæäžãã¹ã
ããµã³ãã³èªå°äœããã³ã¢ã»ãã«ãµãªãã«é žã®é
ããåç¬ã§æäžããå Žåã«ã¯æå°ã®è¬çåŠçäœçš
ãã瀺ããªããããªéãŸã§æžããããšãã§ããåŸ
ã€ãŠé«æäžéã®ãããã®è¬ç©ã«ããåŒãèµ·ããã
ãå¯äœçšãäœæžã§ããããšã§ãããã¢ã»ãã«ãµãª
ãã«é žã¯éåžžã®æäžéã§æãŸãããªãå¯äœçšãã
ãšãã°ãããªãã€ãã·ãŠ ãžã€ãŒãã« ãªã ã¯
ãªãã«ã« ãã¢ãŒãã³ããžãŒïŒãBritish Journal
of Clinical PharmacologyãïŒç¬¬10å·»è£éºïŒ
ïŒ1980幎ïŒãããã³æççå€ãé®çå€ã®å¯äœçšã«é¢
ããåœéåŠäŒïŒInternational Meeting on side
Effects of AntiinflammatoryãAnalgesic
DrugsïŒãŽãšããã1982幎ïŒæ13ã15æ¥ãèŠæšé
ã«åç §ãããããããšãã°åæ¯ãã¢ã¬ã«ã®ãŒæ§è
麻ç¹ãé®çå€æ§è èç çããã³æ¶åæ§æœ°çãåŒã
èµ·ããå¯èœæ§ãããããšãç¥ãããŠããã®ã§ãã®
ããšã¯æ¥µããŠéèŠã§ãããããã«ããµã³ãã³èªå°
äœã¯æãŸãããªãå¯äœçšã瀺ãå¯èœæ§ããããä»
ãé©ãã¹ãããšã¯æ¬çºæã«ããçµåããçæç©ã
çšããããšã«ãããããµã³ãã³èªå°äœã®éã°ãã
ã§ãªã人ã«å¯ŸããŠå¿ èŠãªã¢ã»ãã«ãµãªãã«é žã®æ
äžéã培åºçã«æžããããšãå¯èœã§ããã®ã§ãäž
è¬çãªæ¯ç©åŠç蚱容æ§ã«ãããŠããäžå±€å€§ããªæ¹
åããªããããããã«ã€ããŠã¯æŽã«äžèšãåç §ã
ãããã é©åœãªããµã³ãã³èªå°äœã®äŸã¯åŒããã ãåŒ
äžãåºR1ããã³R3ã®äžæ¹ã¯ïŒãïŒåã®ççŽ åå
ãæããçŽéã¢ã«ãã«ãïŒÏâïŒïŒâãªããœã¢ã«ã
ã«ãŸãã¯ïŒÏâïŒïŒâããããã·ã¢ã«ãã«åºã§ã
ãããããŠä»ã®ïŒåã®åºR2ããã³R3ãŸãã¯R1ã
ãã³R2ã¯ããããR1ããã³R3ã®äœçœ®ã«ïŒãïŒå
ã®ççŽ ååãããããŠR2ã®äœçœ®ã«ïŒãïŒåã®ç
çŽ ååãæãããããŠãããã®ïŒã€ã®ã¢ã«ãã«çœ®
æåºã«å«ãŸããççŽ ååã®åèšãæé«ã§10åã§ã
ããããªçŽéãŸãã¯åæéã¢ã«ãã«åºã§ãããã®
ïŒïŒïŒïŒïŒâããªçœ®æååç©ã§ããã ããã«ãããŠã¯å¥œãŸããåŒã®ããµã³ãã³åå
ç©ã¯R1ãŸãã¯R3ãïŒåãŸãã¯ïŒåãççŽ ååã
æããã¢ã«ãã«ãïŒÏâïŒïŒâãªããœã¢ã«ãã«ãŸã
ã¯ïŒÏâïŒïŒâããããã·ã¢ã«ãã«åºãè¡šããã
ãããŠïŒåã®ã¢ã«ãã«çœ®æåºR2ããã³R3ããŸã
ã¯R1ããã³R2ã¯äžç·ã«ãªã€ãŠïŒãïŒåã®ççŽ å
åãå«ããããªååç©ã§ããã ãããã®ååç©ã®ãã¡ã§ç¹ã«å¥œãŸãããã®ã¯
R1ãŸãã¯R3ã®äœçœ®ã«ããã·ã«ãïŒâãªããœãã
ã·ã«ãŸãã¯ïŒâããããã·ããã·ã«åºãæããå
åç©ã§ããããããã«ã¯ç¹ã«ïŒâããã·ã«âïŒïŒ
ïŒâãžã¡ãã«ããµã³ãã³ãïŒâïŒïŒâããããã·
ããã·ã«ïŒâïŒïŒïŒâãžã¡ãã«ããµã³ãã³ãïŒâ
ïŒïŒâãªããœããã·ã«ïŒâïŒïŒïŒâãžã¡ãã«ããµã³
ãã³ãïŒïŒïŒâãžã¡ãã«âïŒâïŒïŒâããããã·
ããã·ã«ïŒããµã³ãã³ãïŒïŒïŒâãžã¡ãã«âïŒâ
ïŒïŒâãªããœããã·ã«ïŒããµã³ãã³ãïŒâïŒïŒâã
ãããã·ããã·ã«ïŒâïŒâã¡ãã«âïŒâãããã«
ããµã³ãã³ããã³ïŒâïŒïŒâãªããœããã·ã«ïŒâïŒ
âã¡ãã«âïŒâãããã«ããµã³ãã³ãå«ãŸããã ããïŒã€ã®é©åœãªããµã³ãã³çŸ€ã¯åŒïŒãã ã
åŒäžãã¯ïŒãïŒåã®ççŽ ååãæããã¢ã«ãã«
åºãè¡šããïŒã®ååç©ããæãã åŒããã³ã®ãªããœã¢ã«ãã«ããµã³ãã³ãã
ã³åŒã®ããããã·ã¢ã«ãã«ããµã³ãã³ã«é¢ããŠ
ã¯ããèªäœã䜿çšããå¿ èŠã¯ãªããåŒããã³
ã«ãããŠå®çŸ©ããã眮æåºãæããæ²»çäžæŽ»æ§ãª
ããµã³ãã³ååç©ãäœå ã§åã«çäœå å€æã«ãã€
ãŠæŸåºã§ãããããªãããã©ãã°ã®åœ¢æ ã§ããã
ã䜿çšããããšãå¯èœã§ããããã®ããã«é©åœã§
ãããããã®äŸã¯ã«ã«ããã«åºãåŒïŒïŒïŒãã
ãåŒäžãR4ããã³R5ã¯ããããïŒåãŸã§ã®ççŽ
ååãæããã¢ã«ãã«åºãè¡šãããããŸãã¯äžç·
ã«ãªã€ãŠãšãã¬ã³ãããªã¡ãã¬ã³ãŸãã¯ããã©ã¡
ãã¬ã³åºãè¡šããïŒïŒç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé åç §ïŒ
ã®æ§é èŠçŽ ã«ãã眮æãããŠãããããªã¢ã»ã¿ãŒ
ã«åããããªããœã¢ã«ãã«ããµã³ãã³ãããã³ã
ãããã·ã«åºã®ä»£ããã«åŒR6âCOââïŒãã
ãåŒäžãR4ã¯ïŒåãŸã§ã®ççŽ ååãæããã¢ã«
ãã«åºãããšãã«ã眮æãããããšãã«ãããªãž
ã«ãŸãã¯çœ®æãããããªãžã«ãè¡šããïŒã®æ§é èŠ
çŽ ãæããâã¢ã·ã«åãããããããã·ã«ã¢ã«
ãã«ããµã³ãã³ã§ããã ã¢ã»ãã«ãµãªãã«é žã®é©åœãªè¬çåŠçã«èš±å®¹ã
ããå¡©ã¯è¬çåŠçã«èš±å®¹ãããéå±éœã€ãªã³ãã¢
ã³ã¢ããŠã ãã¢ãã³éœã€ãªã³ãŸãã¯ç¬¬ïŒçŽã¢ã³ã¢
ããŠã éœã€ãªã³ãšã®å¡©ã§ãããã¢ã«ã«ãªéå±ããš
ãã°ãªããŠã ããããªãŠã ããã³ã«ãªãŠã ããã³
ã¢ã«ã«ãªåé¡éå±ããšãã°ãã°ãã·ãŠã ããã³ã«
ã«ã·ãŠã ã®å¡©ã奜ãŸããããä»ã®éå±ããšãã°ã¢
ã«ãããŠã ãäºéããã³éã®éœã€ãªã³ã®åœ¢æ ã䜿
çšããããšãã§ããã è¬çåŠçã«èš±å®¹ãããã¢ãã³ã®éœã€ãªã³ã¯ç¬¬ïŒ
çŽã第ïŒçŽãŸãã¯ç¬¬ïŒçŽã¢ãã³ããšãã°ã¢ã«ãã«
ã¢ãã³ããšãã°ã¡ãã«âããžã¡ãã«âãããªã¡ã
ã«âããšãã«âããžããã«âãããªã€ãœãããã«
âãâã¡ãã«ããã·ã«âããã³ãžã«âãβâã
ãšãã«ãšãã«ã¢ãã³ããšãã¬ã³ãžã¢ãã³ããžãšã
ã¬ã³ããªã¢ãã³ããããªãžã³ãã¢ã«ããªã³ããã
ã©ãžã³ãã¢ãâããžâããã³ããªãšã¿ããŒã«ã¢ã
ã³ããšãã«ãžãšã¿ããŒã«ã¢ãã³ãâããã«ãšã¿
ããŒã«ã¢ãã³ãªã©ã®éœã€ãªã³ã§ãããä»ã®é©åœãª
ã¢ãã³ã®å¡©ã¯ãªãžã³ããã³ã¢ã«ã®ãã³ã®å¡©åºæ§ã¢
ãã³å¡©ã§ãããé©åœãªè¬çåŠçã«èš±å®¹ããã第ïŒ
çŽã¢ã³ã¢ããŠã éœã€ãªã³ã®äŸã¯ããã©ã¡ãã«ã¢ã³
ã¢ããŠã ãããã©ãšãã«ã¢ã³ã¢ããŠã ããã³ãã³
ãžã«ããªã¡ãã«ã¢ã³ã¢ããŠã ã§ããã äžæ¹ã®ããµã³ãã³èªå°äœãããã³ããäžæ¹ã®ã¢
ã»ãã«ãµãªãã«é žæåã¯ãŸãè¶ éå æçå¹æãé
æããããã«åæã«æäžããããšãã§ããããã
ãããšããããã®æåãéœåã®ããæéã«é 次ç
ã«æäžã§ãããããªãé©åœãªåœ¢æ ã®æ··åç©ã§ãã
ããšãã§ãããšããŠããå¥ã ã®åœ¢æ ã®è¬éåäœãš
ããŠæäžããã®ã奜ãŸãããè¬éåäœã¯åºäœç¶ã®
è¬å€åœ¢æ ããšãã°ã«ãã»ã«å€ïŒäžè¬çã«ã¯è¬åŠç
賊圢å€ãå«æããªããã€ã¯ãã«ãã»ã«ãå«ãïŒã
é å€ïŒè¢«èŠé å€ããã³äžžå€ãå«ãïŒãŸãã¯åå€ã®
圢æ ã§ããããšãã§ããããã«ãããŠã«ãã»ã«å€
ã䜿çšãããå Žåã«ã¯ã«ãã»ã«ç©è³ªã¯è³Šåœ¢å€ã®æ©
èœã瀺ããšèãããããããŠå 容ç©ã¯ããšãã°ç²
æ«ãã²ã«ãä¹³æ¿æ¶²ãåæ£ç©ãŸãã¯æº¶æ¶²ã®åœ¢æ ã§ã
ã€ãŠããããããããªããããããã®ææã®è¬åŠ
ç賊圢å€ãšãšãã«èšç®éã®æŽ»æ§ååç©ãå«æãã
ãããŠæŽ»æ§ååç©ã®æŸåºãé 次çã«çèµ·ãããã
ãªæ§è³ªãæãããïŒçš®ã®æŽ»æ§ååç©ã®çµå£çåŠæ¹
ç©ã®è£œé ããããšãç¹ã«æå©ã§ããããŸãç°¡åã§
ããããŸãçŽè žåŠçœ®ã®ããã®é©åœãªåŠæ¹ç©ïŒå
å€ïŒã䜿çšããããšãã§ãããåæ§ã«çµç®çãã
ã³éçµå£çïŒè ¹è å ãéèå ãç®äžãŸãã¯çè
å ïŒæ³šå°æ¶²ãå¯èœã§ããããã®å Žåã«ã¯ããšãã°
é©åœãªå€å®€æ³šå°è£ 眮ã䜿çšããããšãã§ããã ãã®åã®çµåããçæç©ã¯éåžžã®æ¹æ³ã«ãã補
é ããããšãã§ãããæ¬çºæã«ãã掻æ§ååç©ã®
é 次çæŸåºïŒçäœå å©çšçïŒã¯éåžžã®æ¹æ³ã§ãã
ãšãã°ãµãã«ãŒãããã¯ã¹ããã³ã¹ãã€ãµãŒèã
ã¢ãŒãããªã€ãã€ãã·ãš ãã¯ããã®ãš
ãSuckerãFuchsããã³Speiserè
ãPharmazeutische TechnologieãïŒè¬åŠæè¡ïŒã
第424é ïŒ1978幎çºè¡ãã·ãŠã¿ããã¬ã«ãïŒã«åŸ
ã€ãŠãå»è¬ãšããŠã¢ã»ãã«ãµãªãã«é žãŸãã¯ãã®
å»åŠçã«èš±å®¹ãããå¡©ããšãã°ïŒ€ïŒïŒ¬âãªãžã³ã¢
ãã¢ã»ãã«ãµãªã·ã¬ãŒããå«æããé å€ãäžžå€ãŸ
ãã¯é¡ç²å€ããæå©ã«ã¯ç²æ¶²åæ³æ§ç©è³ªãæš¹èã
ãšãã°ããªã¹ãã¬ã³ãŸãã¯èš±å®¹æ§ãä¿é²ããä»ã®
é垞䜿çšãããè¬å€ãšçµåãããŠæŽ»æ§ååç©ãšã
ãŠããšãã°ãã³ããã·ãã€ãªã³ãå«æããã³ãŒã
ã€ã³ã°ïŒå€ç®ïŒã§è¢«èŠããããšã«ããéæã§ã
ããè¯éšåãšããŠäœ¿çšãããé å€ãäžžå€ãŸãã¯é¡
ç²å€ã¯éåžžã®æ¹æ³ã«ãã補é ããããšãã§ããã
ããŠè³Šåœ¢å€ããã³ä»ã®é垞䜿çšãããè£å©å€ããš
ãã°æŸ±ç²ããšãã°ãããããããšããããããŸã
ã¯å°éºŠã®æŸ±ç²ãã»ã«ããŒã¹ãŸãã¯ãã®èªå°äœç¹ã«
埮æ¶æ§ã»ã«ããŒã¹ãã·ãªã«ãçš®ã ã®ç³ããšãã°ä¹³
ç³ãçé žãã°ãã·ãŠã ããã³ïŒãŸãã¯çé žã«ã«ã·
ãŠã ãå«æããããšãã§ãããããšãã°ãã³ãã
ã·ãã€ãªã³ãå«æããå€ç®ã¯ããšãã°è¬åŠçæè¡
ã«ãããŠé垞䜿çšãããæ¹æ³ããšãã°å§çž®ã液浞
ãŸãã¯æµååºæ³ã«ããããŸãã¯ãã©ã ã³ãŒãã€ã³
ã°ã«ããè¯éšåã«é©çšããããšãã§ãããå€ç®ã®
溶液ã¯éåžžãŒã©ãã³ãã¢ã©ãã¢ãŽã ãããªããã«
ãããªãã³ãåæã»ã«ããŒã¹ãšã¹ãã«ãè¡šé¢æŽ»æ§
ç©è³ªãå¯å¡å€ãè²çŽ ããã³åœæ¥ã«ãããŠäœ¿çšãã
ãåæ§ã®ä»å ç©ãæ·»å ããç³ããã³ïŒãŸãã¯æŸ±ç²
ã·ãããããæãã 掻æ§ååç©ã®é 次çæŸåºã¯ãŸããµãã«ãŒæ°ã
ïŒäžèšæç®åç §ïŒã«ããåæ§ã«èšèŒãããŠããã
ããªéå±€é ïŒãã®çšèªã«ã¯åå¿æ§è¯é å€ãå«ãŸã
ãïŒã䜿çšããããšã«ããéæã§ãããã®å Žåã
ãæ©ãåžåãããå±€ã¯æå©ã«ã¯åæ§ã«ç²æ¶²åæ³æ§
ç©è³ªãŸãã¯ä»ã®èš±å®¹æ§ãä¿é²ããéåžžã®è¬å€ãšãš
ãã«ããµã³ãã³ãå«æããããã®è¬å€ã®åœ¢æ ã«ã
ããŠã¯ã掻æ§ååç©ã®æŸåºã¯é垞䜿çšãããé©åœ
ãªè£å©å€ããšãã°äžèšã«è©³è¿°ããããã®ã䜿çšã
ãŠé å€ã®å±€ããã®æŸåºé床ã«å·®ãçããããããš
ã«ããéæã§ãããïŒçš®ã®æŽ»æ§ååç©ããšãã°ã
ã³ããã·ãã€ãªã³ããã³ã¢ã»ãã«ãµãªãã«é žã®æ®µ
éçãªæŸåºã¯ããŸãã¢ã»ãã«ãµãªãã«é žãå«æã
ãæåãé 延å€ãå«æããããšã«ãã€ãŠãéæã
ãããã®é 延å€ã¯é©åœãªå Žåã«ã¯ããšãã°ã»ã«ã
ãŒã¹ãŸãã¯ããªã¹ãã¬ã³æš¹èãŸãã¯ã€ãªã³äº€æäœ
ã«åºã¥ãã浞éèã®åœ¢æ ã§äœ¿çšããŠãããããŸã
è液ã«æµæããããŸãã¯æŸåºãé ããããããªã
ã€ã¯ãã«ãã»ã«ã®åœ¢æ ã§äœ¿çšããŠããããããã
ãªããã¢ã»ãã«ãµãªãã«é žãå«æããè¯éšåã¯ãŸ
ãæŸåºãé ãããããšãã§ãããããªãããšãã°
ããªã¡ã¿ã¯ãªã«ãšã¹ãã«ïŒãŠãŒãã©ã®ããã
Eudragit(R)ãå«ãã³ãŒãã€ã³ã°ãæœãããšãã§ã
ãã é垞䜿çšããããã¹ãŠã®æµã調ç¯å€ããªããã
ã«ããè¬å€ããªãã¡æœ€æ»å€ããšãã°ã¹ãã¢ãªã³é ž
ãã°ãã·ãŠã ãããã³é¢åå€ããã®è¬å€åœ¢æ 補é
ã®ããã«äœ¿çšããããšãã§ããã ã¢ã»ãã«ãµãªãã«é žã®ããµã³ãã³èªå°äœããšã
ã°ãã³ããã·ãã€ãªã³ã«å¯Ÿããééæ¯ã¯åºãç¯å²
å ã§å€ããããšãã§ãããç¹å®ã®çµåããã«å¯Ÿã
ãŠäœ¿çšãããæ£ç¢ºãªå²åã¯äžèšã®å®éšæäœã䜿çš
ããŠå®¹æã«æ±ºå®ããããšãã§ãããäžè¬çã«ã¯ã¢
ã»ãã«ãµãªãã«é žïŒéééšã«å¯Ÿããããµã³ãã³èª
å°äœããšãã°ãã³ããã·ãã€ãªã³ã®ééæ¯ã¯æäœ
çŽ0.1奜ãŸããã¯æäœçŽ0.3ã0.5ãç¹ã«æäœçŽïŒã
ãæé«çŽ50奜ãŸããã¯æé«çŽ10ãŸã§ã§ããããŸã
ããµã³ãã³èªå°äœã®æäžããã³ã¢ã»ãã«ãµãªãã«
é žã®æäžãšã®æé©ã®æéééããŸãã¯è¬åŠçåŠæ¹
ç©ããã®æé©ã®æŸåºé床ã決å®ããããšãããã
ã®å®éšæäœã䜿çšããããšã«ããå¯èœã§ãããã
ãµã³ãã³èªå°äœããšãã°ãã³ããã·ãã€ãªã³ãæ
åã«æŸåºããããããã€ãã«15åãªããïŒæéåŸ
ã«ã¢ã»ãã«ãµãªãã«é žæåãæŸåºããããããã
çŽ20ã90åããããŠç¹ã«30ã60åã®ééãç¹ã«å¥œ
ãŸããããã¡ããæäžãããè¬éã¯çš®ã ã®å åã
ãšãã°åŠçãããçç©äœïŒããªãã¡äººãŸãã¯å
ç©ã幎什ãäœéããã³äžè¬çãªå¥åº·ç¶æ ïŒãçç¶
ã®é節ããæ²»çãã¹ãçŸæ£ãïŒååšããå Žåã«ã¯ïŒ
ä»ã®è¬å€ãçšããŠã®åææ²»çã®æ§è³ªãæ²»çåæ°ãª
ã©ã«ããäžèšã®è¬éã¯äžè¬çã«ïŒæ¥ã«ïŒåãŸã§ã
ãããŠå¥œãŸããã¯ïŒæ¥ã«ïŒåãïŒåæäžãããã
ããããã®æŽ»æ§ååç©ã®ééæ¯ã¯äžèšã«ç€ºããã
ç¯å²å ã«å ¥ãã¹ãã§ãããæåã®éã¯äžèšã«ç€ºã
ããç¯å²å ã«å ¥ãã¹ãã§ããããããŠæåã®éã¯
æ²»çãããçäœã蚱容ããããããªæå¹æäžéã®
ç¯å²å ã«ããã¹ãã§ããã ããšãã°ã¢ã»ãã«ãµãªãã«é žã®å¥œãŸããæäžé
ã¯ã人ã«åç¬ã§æäžããå Žåã500ã2000mgç¹ã«
1000mgã§ãããïŒæ¥ã«ïŒãïŒåæäžãããããã³
ããã·ãã€ãªã³ã®å¥œãŸããæäžéã¯ã人ã«åç¬ã§
æäžããå Žåã200ã800mgç¹ã«300ã600mgã§ã
ããïŒæ¥ã«ïŒãïŒåæäžãããã ãã¢ã»ãã«ãµãªãã«é žã®ãã³ããã·ãã€ãªã³ã«å¯Ÿ
ãããããã®ééæ¯ããé©åãªéãæ£ç¢ºã«èšç®ã
ãããšãã§ãããåŸã€ãŠé©åœãªæ²»çã¯æ¬çºæã«ã
ãçµåããçæç©ã®åç¬æäžããšãã°ïŒåãïŒå
ãŸãã¯æ°å奜ãŸããã¯ïŒãïŒåæäžããããšãã
æãããã®åç¬æäžéã¯ããããããµã³ãã³èªå°
äœç¹ã«ãã³ããã·ãã€ãªã³ã100ã600mgã奜ãŸã
ãã¯æäœ200mgããããŠç¹ã«400mgãŸã§ãå«æãã
ãããŠã¢ã»ãã«ãµãªãã«é žã10ã2000mgããšãã°
400mgãŸã§ãå«æããããŸãã¯ããã«çžåœããé
ã®å¡©ãå«æããããã®å Žåã«ãã®éã¯ãã¡ããå
ç¬æäžã®åæ°ãªãã³ã«æ²»çãããã¹ãçŸæ£ã«ãã€
ãŠç°ãªãããããŠåç¬æäžã¯ããšãã°åæã«æäž
ãããæ°åã®é å€ãå«ãããšãã§ãããããããª
ããæ¬çºæã«ãããŸãç¹ã«å°éã®ã¢ã»ãã«ãµãªã
ã«é žïŒããšãã°ïŒæ¥ããã10ã50mgãŸãã¯ãã以
äžïŒã®æäžãææãããå Žåã«è¯å¥œãªçµæãåŸã
ããšãã§ããããã«ãªãããã®çµæã¯åéã®ã¢ã»
ãã«ãµãªãã«é žãåç¬ã§æäžããå Žåããããªã
è¯å¥œã§ããã æ¬çºæã«ããè¬å€ã¯æ¢ç¥ã®æè¡æ 圢æå€ããã³
è¡å°æ¿åéé»å®³å€ãšåæ§ã®æ¹æ³ã§äœ¿çšããããšã
ã§ãããçäœå ã§ã®äœ¿çšã¯åèããã³éèã§ã®è¡
é€ åœ¢æãé»æ¢ããããã«ãããšãã°äžæçãªèè¡
æ§çºäœãé»æ¢ããããã«ããããŠå¿çæ¢å¡ããã³
çºäœåŸã®ããããŠåè硬åçã®é·æçäºé²ã®ãã
ã«ããããŠãŸãå€ç§æè¡åŸã®è¡æ çãé²æ¢ããã
ãã®åŠçœ®ãšããŠããŸã転移ãé»æ¢ãŸãã¯äœæžãã
ããã®çã®åŸåŠçœ®ãšããŠäººããã³åç©ã«æäžãã
ããšããæãã 人工å¿èºè£ 眮ãæããæ£è ããã³è èéæãšé¢
ä¿ã®ããæ£è ãžã®æäžãå¯èœã§ãããåæ§ã«äººå·¥
å¿èåŒã人工è¡ç®¡ãªã©ãæããæ£è ãžã®æäžãå¯
èœã§ããããã¡ããäžèšã®ããããã®æåã¯ããš
ãã°è¡æµä¿é²ïŒéæ¬ æ§è·è¡ïŒããã³é®çããã³æ
ççäœçšïŒæ ¢æ§çççãå«ãïŒã®ããã®å®éäžã®
æ瀺ã«åŸã€ãŠæäžããããšãã§ãããæççæ§ã®
補å€ã®å Žåã«ã¯ããµã³ãã³èªå°äœã®æåã«å¯Ÿã
ãæ¯ã¯äžè¬çã«0.1ãïŒã§ããããä»æ¹ä»ã®è£œå€
ã®å Žåã«ã¯äžè¬çã«ããã¯0.5ã50ã§ããã çäœå ã«ãããç 究 ãã³ããã·ãã€ãªã³ããã³ã¢ã»ãã«ãµãªãã«é ž
ã®çµåããã¯ã¬ãŒã¶ãŒãçšããŠã©ããè žéèã®å°
åèã«ãããŠè¡ç®¡å è¡æ çãåŒãèµ·ãããããªå®
éšèšç»ã䜿çšããŠçäœå ã§è©äŸ¡ãããããã®æ¹æ³
ã¯æ¬çºæã«ããçµåããçæç©ã«å¯Ÿããé©åœãªå®
éšã¢ãã«ã§ãããçäœé¡åŸ®é¡æ€æ»æ³ãçšããåæ
ã«ããè©äŸ¡ãè¡ããããããã€ãã€ãŒãïŒ
ïŒãNatureãïŒç¬¬218巻第887é ïŒ1968幎ïŒããã³
ããã¢ã¹ã¿ã·ã¹ãïŒãHaemostasisãïŒç¬¬13巻第61é
ïŒ1983幎ïŒããã³ãã¢ã€ã¢ãŒã«ã·ãŒãšã¹ ã¡ãã
ãµã€ãïŒãIRCS Med.Sci.ãïŒç¬¬12巻第91é
ïŒ1984幎ïŒãã è©Šéšç©è³ªã¯0.9ïŒ å¡©åãããªãŠã 溶液ãããã¯
ïŒïŒ ã«ã«ããã·ã¡ãã«ã»ã«ããŒã¹ããµãŒã瀟補
ïŒServaïŒããã€ãã«ãã«ã°ããå«æããŠããããš
ããŠçµå£çã«ããè ¹è å ã«ããŸãã¯éèå ã«æäž
ãããå¯Ÿç §åç©ã¯è©Šéšç©è³ªãçšããã«å¯Ÿå¿ããæ¹
æ³ã§åŠçããã䜿çšããå®éšåç©ã¯éæ§ãŸãã¯é
æ§ã®ã¹ãã¬ã€ã°âããŠã¬ã€ç³»ãŸãã¯ãŠã€ã¹ã¿ãŒç³»
ã©ããã§ãã€ãã ã¬ãŒã¶ãŒã§åŒãèµ·ããããè¡æ çã¢ãã«ã«ãã
ãŠãã³ããã·ãã€ãªã³ãä»ã®ããµã³ãã³èªå°äœã
ãã³ã¢ã»ãã«ãµãªãã«é žãçšããç 究ã¯äœéçŽ
200ïœã®éæ§ã¹ãã¬ã€ã°âããŠã¬ã€ç³»ã©ããã«ã
ããŠè¡ããããç 究ãããåç©ã«0.1mgã®ã¢ãã
ãã³ç¡«é žå¡©ã溶液ãšããŠç®äžçã«åæè¬ãããã
ãŠäœéKgãããã±ã¿ãã³å¡©é žå¡©100mgããã³ãã·
ã©ãžã³ïŒmgãè ¹è å æäžããŠéº»é ããããã®ç 究
ã§ã¯çŽåŸçŽ13ÎŒïœã®è žéèã®å°åèããã³å°éè
ãè±æ°ããæµåãã©ãã€ã³ã§è¢«èŠããŠäœ¿çšããã
4Wã¢ã«ãŽã³ã¬ãŒã¶ãŒãã¹ãã¯ãã© ãã€ãžãã¯
ã¹ç€ŸïŒSpectra Physicsããã«ã ã·ãŠã¿ããïŒ
補ãã®å æãå éé©å¿èª¿ç¯è£ 眮ãããŒãã€ãŒãžãŒ
瀟ïŒBTG瀟ãããŠãããïŒè£œããçšããŠé¡åŸ®é¡
ãICM405ãLDâãšããã©ã³ãïŒLDâEpiplandïŒ
40ïŒ0.60ïŒãã¢ã€ã¹ïŒZeissïŒç€Ÿè£œãªãŒãã«ã³ã
ãã³ãã®é転å è·¯ã«å軞çã«å°å ¥ããã䜿çšãã
æ³¢é·ã¯514.5nïœã§ããã30.5ïœïŒ·ã®å¯Ÿç©ã¬ã³ãºã
ããé«ããšãã«ã®ãŒãæãããïŒåã®ç §å°ããã
ã®é²å æéã¯1/15ç§ã§ãã€ãããã¹ãŠã®æž¬å®æäœ
ã¯ãããªã«ã¡ã©ïŒããªãã³ã³ããŠãŒãããœããŒç€Ÿ
補ã±ã«ã³ïŒã«èšé²ãããèšé²èšããœããŒç€Ÿè£œãŠãŒ
ããã€ãã¯ïŒïŒµâmaticïŒ3/4â³ãã«ä¿åãããŠã
ããè©Šéšç©è³ªã¯çµå£æäžã®å Žåå®éšéå§ã®ïŒæé
ãŸãã«ããããŠéèå æäžã®å Žåãã®10åãŸãã«
çš®ã ã®æäžéã§å®éšåç©ã«æäžããå¯Ÿç §åç©ã«ã¯
åéã®ãã©ã»ããŒãæäžãããã€ãã®ããã«ããŠ
äžèšã®ç©è³ªãæäžãããããªãã¡(1)åç¬æäžãšã
ãŠ(2)çµåãããšããŠäžç·ã«ã(3)æåã«ã¢ã»ãã«ãµ
ãªãã«é žãããããŠïŒæéåŸã«ãã³ããã·ãã€ãª
ã³ãŸãã¯ä»ã®ããµã³ãã³èªå°äœãããããŠ(4)æå
ã«ãã³ããã·ãã€ãªã³ãŸãã¯ä»ã®ããµã³ãã³èªå°
äœãããããŠïŒæéåŸã«ã¢ã»ãã«ãµãªãã«é žãæ
äžããïŒè¡š1aïŒãè¡š1bã«ã¯çš®ã ã®æéééã®å¹æ
ã瀺ããããè¡š1cã«ã¯ä»ã®ããµã³ãã³èªå°äœã®äœ
çšãèŠçŽãããŠããã è© äŸ¡ äžå®ã®è¡æ ãèªçºããããã«å¿ èŠãªç §å°åæ°ã
æ°ãããããç §å°é »åºŠã¯ïŒåæ¯ã«ïŒåã®ç å€ãç
ããããã«èª¿ç¯ãã芳å¯æéäžã«çæãããæäœ
è¡ç®¡çŽåŸã®1/4ã®å€§ãããæãããã¹ãŠã®è¡æ ã
èšæ°ã枬å®ããã å®éšçµæã¯Ï2ãã¹ãã䜿çšããçµ±èšåæã«ä»ã
ãïœãšã« ã«ããªãŒã¹ã«ã¶æ°èããã€ãªã¡ããª
ãŒããL.Cavalliâsforzaæ°èãBiometrieïŒçç©çµ±
èšåŠïŒãã·ãŠã¿ããã¬ã«ã1969幎çºè¡ã第49é ã
ãã³ãã以éïœã çµ æ çµæã¯è¡š1aãïœã«èšé²ããããã¢ã»ãã«ãµãª
ãã«é žãŸãã¯ãã³ããã·ãã€ãªã³ïŒmgïŒKgã®åç¬
çµå£æäžã«ããäœçšã¯ææã§ã¯ãªããããã³ãã
ã·ãã€ãªã³ã¯è¡æ 圢æã«å¯ŸããŠ20ïŒ ã®æå¶ã瀺
ããäž¡æ¹ã®ç©è³ªã¯10mgïŒKgã®çµå£æäžéã§ææãª
äœçšãæããããã³ããã·ãã€ãªã³ããã³ã¢ã»ã
ã«ãµãªãã«é žã®åææäžã¯äžèšã®ã¬ãŒã¶ãŒã¢ãã«
ã«ãããŠäœçšã瀺ããªãã€ãããã®ããšã¯æåã«
ã¢ã»ãã«ãµãªãã«é žãæäžããïŒæéåŸã«ãã³ã
ãã·ãã€ãªã³ãæäžããå Žåãåæ§ã§ãã€ããã
ããšã¯å¯Ÿç §çã«æåã«ãã³ããã·ãã€ãªã³ããã
ããŠïŒæéåŸã«ã¢ã»ãã«ãµãªãã«é žãæäžããå Ž
åã«ã¯ãã©ããè žéèã®å°åèããã³å°éèã«ã
ããŠã¬ãŒã¶ãŒã§èªçºãããè¡æ çã¢ãã«ã«ãããŠ
æäžéäŸåæ§ã®ææãªäœçšã瀺ããããåç¬æäž
ãšæ¯èŒããŠãã®é 次çæäžã®è¶ éå æçå¹æã¯å¯Ÿ
ç §ãšæ¯èŒããŠå€åã®ããŒã»ã³ããã極ããŠæçœã§
ããïŒè¡š1aïŒã è¡š1bã«èšèŒãããçµæã¯ïŒã€ã®åç¬æäžã®é
ã§éžã¶ããšãã§ããæéçééã«ã¯åºãç¯å²ãã
ãããšã瀺ããã15åãªãã180åãæé©ã§ããã
æ¬çºæã«ããå¹æã¯ä»ã®ããµã³ãã³èªå°äœïŒç¹èš±
è«æ±ã®ç¯å²åç §ïŒãçšããŠãéæããããšãã§
ãããã®å Žåã«ã¯ãããã¯ã¢ã»ãã«ãµãªãã«é žãš
ãšãã«æäžããããããã ãéœåã®ããæéã«æ
ãå€ããŠæäžãããããããã®ããµã³ãã³èªå°äœ
ã®éžæã«é¢ããæè¡æ 圢æäœçšã¯è¡š1cã«èšé²ãã
ãŠããã ãã®é 次çæäžã¯ïŒã€ã®å¥ã ã«å¶åŸ¡ã§ããéšå±
ãæããåæ¥äžå ¥æå¯èœãªçæµè£ 眮ãããšãã°ã
ã©ãŠã³ç€ŸïŒBraunãã¡ã«ã¹ã³ã²ã³ïŒã«ããäŸçµŠã
ãããã®ãã¿ã€ã ã¹ã€ããã«ããåé¢ããããã«
èæ¡ãããã¢ãŒã¿ãŒé§åäŸçµŠåšãè£ åããŠããã
ã䜿çšããŠè¡ãããšãã§ããããã®çæµè£ 眮ã®ïŒ
ã€ã®éšå±ã¯ãããããã³ããã·ãã€ãªã³æº¶æ¶²ïŒã©
ããKgããããã³ããã·ãã€ãªã³10mgã«çžåœã
ãïŒããã³ã¢ã»ãã«ãµãªãã«é žæº¶æ¶²ïŒKgãããïŒ
mgã«çžåœããïŒïŒæº¶åªã«å¯ŸããŠã¯äžèšåç §ïŒã§æº
ãããããå°Ÿéèã«ãã³ããã·ãã€ãªã³æº¶æ¶²ã泚
å°ããŠ20ååŸã«ã¢ã»ãã«ãµããªã«é žæº¶æ¶²ã泚å°ã
ãããã«ã¿ã€ã ã¹ã€ããã«ããå¶åŸ¡ãããæ¯èŒå®
éšã«ãããŠã¯äž¡æ¹ã®éšå±ã®æ¶²ãåæã«æ³šå°ããã
çµæã¯çµå£æäžåŸã«åŸããã枬å®å€ã«çžå¿ããŠã
ããããªãã¡é 次çæäžã«ãããŠåŸãããäœçšã¯
åææäžã«ãããŠåŸãããäœçšãããã¯ããã«å€§
ããã€ãã çäœå€ã§ã®ç 究 æ¬æ¥æ¢ç¥ã®æ¹æ³ã«ããè¡å°æ¿åéã枬å®ããã
éæ§å®¶å ïŒèªå®¶é£Œè²ãBASKãSPFãŠã€ã¬ç³»ãçŽ
2.5ã3.5KgïŒãççé£å¡©æ°Žã«æº¶è§£ãããã³ããã·
ãã€ãªã³ããã³ïŒãŸãã¯DLâãªãžã³ã¢ãã¢ã»ã
ã«ãµãªã·ã¬ãŒãã§éèå ïŒè³ã®éèïŒçã®åŠçã
ããã€ãã«è³éèããæ¡è¡ãã3.8ïŒ ãããé žäž
ãããªã ãŠå¡©ã®æº¶æ¶²ãïŒïŒïŒã®å²åã§å ãããã
ãŠãã®æ··åç©ã宀枩ã§45åéã€ã³ããŠããŒãã
ããã€ãã«ãããïŒåéããã1000å転ã§10åé
é å¿åé¢ãããè¡å°æ¿ã«å¯ãè¡æŒ¿ãå«ãäžå±€ãå
é¢ãããããŠäžå±€ãïŒåéããã28000å転ã§10
åéé å¿åé¢ãããåæ§ã«åé¢ããäžå±€ã¯ä»åºŠã¯
è¡å°æ¿ã«ä¹ããè¡æŒ¿ãå«æããŠãããè¡å°æ¿ã«å¯
ãè¡æŒ¿ãïŒmlãããè¡å°æ¿çŽïŒãïŒÃ108åãå«
ãããã«è¡å°æ¿ã«ä¹ããè¡æŒ¿ã§åžéãããã³ãŒã«
ã¿ãŒã«ãŠã³ã¿ãŒãã³ãŒã«ã¿ãŒãšã¬ã¯ãããã¯ã¹ç€Ÿ
補ã¯ã¬ããšã«ãïŒCoulter counterãCoulter
ElectronicsãKrefeldïŒããè¡å°æ¿ã®åéã¯ããŒã³
ïŒBornïŒåéæ€åºèšãã¬ãŒããŒïŒLaborïŒGmbH
補ããã³ãã«ã°ããçšããŠå ã®ééã枬å®ããã
ãšã«ããå åŠçã«è¿œè·¡ãããè©Šéšæ··åç©ã®å®¹éã¯
0.25mlã§ããããããŠæž©åºŠã¯37âã§ãã€ããä¿è·
æ°äœïŒã¢ã«ãŽã³ïŒäžã§ã®ãã¬ãã©ãã€ãé«é液äœ
ã¯ãããã°ã©ãã€ãŒïŒHPLCéçžïŒ£â18ã«ã©ã ïŒ
ã«ãã粟補ããã¢ã©ããã³é žããµãŒã瀟
ïŒServaããã€ãã«ãã«ã°ïŒãïŒÃ10-4MãçšããŠ
åéãåŒãèµ·ããããè¡å°æ¿åéã®å¢å€§ã¯å ã®é
éã«åºã¥ããŠè¿œè·¡ããããã®ç³»ã§æž¬å®ãããå€æ°
ã¯æ倧åéæ¯å¹ ã§ãããçµæã¯è¡šïŒã«èšé²ãã
ãã éæ§ã©ãããããšãŠã€ã¹ã¯ãç³»ïŒHoe
WiskfïŒãçŽ180ïœããã€ãã®è¬ç©ãããªãšãã¬ã³
ã°ãªã³ãŒã«ïŒPEGãååé400ïŒäžãKgãããïŒ
mlã«çžåœãã®çµå£æäžã«ããåŠçããã å®éš(1) ãã³ããã·ãã€ãªã³30mgïŒKgã30ååŸã«
ã¢ã»ãã«ãµãªãã«é žïŒmgïŒKgã å®éš(2) ãã³ããã·ãã€ãªã³30mgïŒKgã30ååŸã«
ã¢ã»ãã«ãµãªãã«é ž10mgïŒKgã å®éš(3) ã¢ã»ãã«ãµãªãã«é ž30mgïŒKgã30ååŸã«
ãã³ããã·ãã€ãªã³30mgïŒKgã å®éš(4) ã¢ã»ãã«ãµãªãã«é ž10mgïŒKgã30ååŸã«
ãã³ããã·ãã€ãªã³30mgïŒKgã å®éš(5) ãã³ããã·ãã€ãªã³30mgïŒKgã30ååŸã«
溶åªã®ã¿ã å¯Ÿç §å®éš(6) è¬ç©ãçšããã«PEG400 ïŒmgïŒKgã ãããã®æäœã18æéåŸã«ããè¿ããæåŸã«æ
äžããŠïŒæéåŸã«ãšãŒãã«éº»é äžã§ã©ãããç ç²
ã«ãããããŠèžå€§åèãé€å»ããã倧åèã®ã»ã°
ã¡ã³ãïŒåç¯ïŒããã ã¡ã«ç·©è¡åããã0.09Må¡©
åãããªãŠã 溶液ïŒPH7.5ïŒïŒmläž24âã§30åé
ã€ã³ããŠããŒããããã€ãã«å€§åèããã®äžæŸã¿
液ã®äžå®éãã€ãã®ããã«ããŠã¢ããã·ã³äºçé ž
ã§èªçºããã人è¡å°æ¿ã®åéã«å¯Ÿããé»å®³å€ãšã
ãŠäœ¿çšãããããªãã¡10æ¥éè¬ç©ããšããªãã€
ããå€èŠäžå¥åº·ãªç·æ§ããã³å¥³æ§ã®å¿é¡è ããå
è åéšã®éèã«æ³šææ·±ãã«ããŠãŒã¬ãæ¿å ¥ããŠæ¡
è¡ãããããŠãã ã¡ã«ãããé žãããªãŠã ïŒ0.38
ïŒ å ããïŒã§æ» èãããè¡å°æ¿ã«å¯ãè¡æŒ¿
ïŒPRPïŒã¯140Ãïœã§15åéé å¿åé¢ããã®ã¡ã«
äžæŸã¿æ¶²ãšããŠåŸãããããã®è¡å°æ¿å«éã¯2.5
ã3.5Ã108ïŒmlã®ç¯å²å ã§ãã€ãïŒã¯ãŒã«ã¿ãŒã«
ãŠã³ã¿ãŒïŒãè¡å°æ¿ã®åéã¯ããŒã³åéæ€åºèš
ïŒã¬ãŒããŒGmbH補ããã³ãã«ã°ïŒãçšããŠå ã®
ééã枬å®ããããšã«ããå åŠçã«è¿œè·¡ãããè©Š
éšæ··åç©ã®ç·éã¯0.25mlã§ãã€ããè¡æŒ¿ãäžèšã®
倧åèäžæŸã¿æ¶²ãšãšãã«37âã§ïŒåéãã¬ã€ã³ã
ãŠããŒãããã€ãã§ïŒÃ10-6Mã¢ããã·ã³äºçé ž
ãçšããŠåéãèªçºãããããããã®å Žåã«æ倧
åéæ¯å¹ ãã倧åèã®ééãé¢æ°ãšããæäžéâ
äœçšæ²ç·ãäœæãããããã®ã°ã©ããã倧åè
0.1mgããåŸãããäžæŸã¿æ¶²ã«ãããæåé掻æ§
ã決å®ããã倧åèã®ééã¯60âã§20æé也ç¥ã
ã倧åèã秀éããããšã«ãã枬å®ãããæ¡è¡åŸ
ïŒãïŒæé以å ã«åé枬å®ãè¡ã€ãã æ¯æ§è©Šéšæ¹æ³ïŒ äžèšãšåæ§ã«ããŠã©ãããçµå£çã«åŠçãã
ãããã ãæäžéãå¢å ããªããè¡ã€ããäžçŸ€ã«
ã¯ãã³ããã·ãã€ãªã³ãæäžãããããŠç¬¬äºã®çŸ€
ã«ã¯ãã³ããã·ãªã³ãã©ã¹ã¢ã»ãã«ãµãªãã«é žã
10ïŒïŒã®ééæ¯ã§æäžãããéåžžã®æšæºçæ¹æ³
ããªãããã€ãŒã«ãããã³ãŠã€ã«ã³ããœã³äž¡æ°
ïŒLitchfieldããã³WilcoxonïŒã1949幎ïŒã«ãã
LD50ãšããŠèŽæ»éãèšç®ããã LD50ïŒãã³ããã·ãã€ãªã³ïŒïŒ1400mgïŒKg LD50ïŒãã³ããã·ãã€ãªã³ïŒã¢ã»ãã«ãµãªãã«
é žïŒ ïŒ1400mgïŒKg çµ æ æ¯ç©åŠç蚱容æ§ã¯äž¡çŸ€ãšãåæ§ã§ãã€ãããã®
ããšã¯æ¬çºæã«ãããã³ããã·ãã€ãªã³ããã³ã¢
ã»ãã«ãµãªãã«é žãšã®çµåããã«å¯ŸããŠè¬åŠçæ
äžéããã³èŽæ»éãšã®æ¯ãã¯ããã«å°ããããšã
æå³ããŠãããåŸã€ãŠãã³ããã·ãã€ãªã³ãŸãã¯
ã¢ã»ãã«ãµãªãã«é žãåç¬ã§æäžããå Žåããã
ããªã奜éœåã§ããã èã®èš±å®¹æ§è©Šéš æ¹ æ³ äœé200ã300ïœã®çµ¶é£ããéæ§ã¹ãã¬ã€ã°ããŠ
ã¬ã€ç³»ã©ãããäžèšãšåæ§ã«ããŠãã³ããã·ãã€
ãªã³ã§ããã®ïŒæéåŸã«ã¢ã»ãã«ãµãªãã«é žã§çµ
å£çã«åŠçãããããŸãã¯ã¢ã»ãã«ãµãªãã«é žã
ãã§çµå£çã«åŠçãããæåŸã«è¬ç©ãæäžããŠ24
æéåŸã«å°åœã«æ²¿ã€ãŠèãåéããæµæ°Žã§æž æµã«
ãããããŠç²èã®ç å€ãæ€æ»ãããèçŒçæ€æ»ã§
æ€åºãããè ºå§èç²èã®ãã¹ãŠã®ç å€ã¯æœ°çãšã¿
ãªããã çµ æ ã¢ã»ãã«ãµãªãã«é žã®è朰çèªçºæ§ã¯ãã³ãã
ã·ãã€ãªã³ã§ååŠçããããšã«ãã圱é¿ãåããª
ãïŒè¡šïŒïŒããã®ããšã¯æ¬çºæã«ããçµåãã
ïŒã¢ã»ãã«ãµãªãã«é žã®ãŸãã«ãã³ããã·ãã€ãª
ã³ãæäžããïŒã®å Žåãèã蚱容ã§ããªããããª
æäžéã«å¯Ÿããè¬åŠçæäžéã®æ¯ããã¢ã»ãã«ãµ
ãªãã«é žã®åç¬ã§æäžããå Žåãããããªãå°ã
ããããæå©ã§ããããšãæå³ããããªããªãã°
è¡šïŒã«ããã°åŸè ã®å Žååäžã®æè¡æ 圢æäœçšã
åŸãããã«ã¯ããªã倧éã®ã¢ã»ãã«ãµãªãã«é žã
å¿ èŠãšããããã§ããã æ ¢æ§çççã®ã¢ãã«ã䜿çšããç 究 æ¬çºæã«ããçµåããã®è¡æµåŠçäœçšãæè¡æ
圢æäœçšãæåéäœçšããã³æççäœçšã¯ãã¯ãª
ãã«ã« ãã¢ã«ããªããžãŒãïŒãClinical
HemorheologyãïŒç¬¬ïŒå·»ç¬¬469ã480é ïŒ1983幎ïŒ
ã®æ¹æ³ã«ãããã©ããã¢ãžãŠãã³ãé¢ç¯çã®ç ç
åŠçã¢ãã«ããã³ãã¯ããªãŠã ãããªã¯ã
ïŒMycobacterium butyricumïŒãçšããŠåŒãèµ·
ãããã«ãããŠ21æ¥éçµå£æäžããã®ã¡æ€æ»ãã
ãããŠé©åœãªåã ã®ç©è³ªã®ãã®ãããªäœçšãšæ¯èŒ
ãããç©è³ªã®æåŸã«æäžããŠïŒæéåŸã«èžå€§åè
ããæ¡è¡ãããè¡æµåŠçäœçšã«é¢ãã枬å®ã®è©³çŽ°
ã¯ãã¹ãŠãã¯ãªãã«ã« ãã¢ã«ããªããžãŒã
ïŒãClinical HemorheologyãïŒç¬¬ïŒå·»ç¬¬263ã273
é ïŒ1984幎ïŒã«èšèŒãããããã«ããŠè¡ã€ããèµ€
è¡çå€åœ¢å¯èœæ§ã¯æµãæ²ç·ã®åæåŸé ãè©äŸ¡ãã
ããšã«ãããã€ã«ããã¡ãŒã¿ããã¬ã³MF4
ïŒMyrenne MF4ãã¬ãŒãã²ã³ç€Ÿãã€ãïŒãçšã
ãŠå®éçã«è©äŸ¡ãããå¥åº·ãªå¯Ÿç §ã©ãããšæ¯èŒã
ãŠé¢ç¯çã©ããã«ãããŠäœäžããŠããèµ€è¡çã®
éæ§ã¯ã¢ã»ãã«ãµãªãã«é žããã³ãã³ããã·ãã€
ãªã³ã«ããåã³å¢å€§ã§ããããšãè¡š5aã«ç€ºãã
ããäžèšïŒçš®ã®ç©è³ªãçµåãããŠåæã«æäžãã
å Žåã§ããè¶ éå æçå¹æã瀺ãããé 次çæäž
ïŒã¢ã»ãã«ãµãªãã«é žã®ïŒæéãŸãã«ãã³ããã·
ãã€ãªã³ãæäžïŒã®å Žåãããã®å¹æã¯ç¹ã«é¡è
ã§ããã äžèšãšåæ§ã®ã¬ãŒã¶ãŒã¢ãã«ã䜿çšããŠæè¡æ
圢æäœçšã枬å®ãããè¡š5bã«ã¯çµæã瀺ãããã
å¥åº·ãªå¯Ÿç §åç©ã«ãããŠè¡æ ã圢æããããã«ã¯
å¹³å2.173ïŒïŒ100ïŒ ïŒã®ã¬ãŒã¶ãŒç §å°ã䜿çšããª
ããã°ãªããªãããé¢ç¯çã«æ£ã€ãåç©ã®å Žåã¯
0.99ïŒïŒ46ïŒ ïŒã®ç §å°ã§å åã§ãããããªãã¡è¡
æ çã®åŸåã¯ç æ°ã«ããã€ãåç©ã«ãããŠå¢å€§ã
ãŠãããè¡æ çã®çµå£ã¯è¬ç©ã§æ²»çããããšã«ã
ããç¹ã«æ¬çºæã«ããçµåããå€ãæäžããããš
ã«ããæžå°ããå¥åº·ãªåç©ã«å¯ŸããŠèŠãåºããã
å³ãšè¿äŒŒããŠããããšãè¡š5bã«ç€ºãããã è¡å°æ¿åéã«é¢ãã枬å®ã¯äžèšã«è©³è¿°ãããã
ãã«ããŠè¡ããããããããªããè¡å°æ¿ã«å¯ãè¡
挿ïŒmläžã§è¡å°æ¿ã®åéãåŒãèµ·ããããã«ã¢ã©
ããã³é žã®ä»£ããã«ã³ã©ãŒã²ã³0.04mgã䜿çšãã
ããã¬ã³ç€Ÿè£œPAååéæ€åºèšïŒMyrenneãã¬
ãŒãã²ã³ïŒããåéæ¯å¹ ïŒåéåŸåïŒã¯ç¡åŠçã®é¢
ç¯çã©ããã®å Žåã«æãé«ããïŒïŒ100ïŒ ïŒãå¥åº·
ãªã©ããã«ãããŠ0.04mgã®ã³ã©ãŒã²ã³ãçšããŠã
åéã¯çèµ·ããªãïŒè¡š5cïŒãèšèŒããçµæã¯é¢ç¯
çã©ããã«ãããŠç çåŠçã«å¢å€§ããåéåŸåã¯
äžèšã®è¬ç©ã«ããäœæžã§ããããšã瀺ããŠããã
é 次çæäžïŒãã³ããã·ãã€ãªã³ããããŠïŒæé
åŸã«ã¢ã»ãã«ãµãªãã«é žïŒã¯ãã®å Žåãè¶ éå æ
çå¹æã瀺ãã æççäœçšã¯äžèšã«åŒçšããããã«ããŠæµ®è «ã
æããè¢ã®äœç©ããã³æšæºçãªå£æ»ææ°ã䜿çšã
ãŠå®éçã«æž¬å®ãããå£æ»ããã³æµ®è «ã®çæã¯äž
èšã®è¬ç©æ²»çã«ããé¡èã«æžå°ãããåŠçãããŠ
ããªãé¢ç¯çã©ãããšæ¯èŒããŠåŠçãããåç©ã®
çç¶ã«ãããçžå¯Ÿçãªæ¹åãè¡šïŒã«ç€ºããããã
ã®å Žåãæ¬çºæã«ããé 次çæäžïŒãã³ããã·ã
ã€ãªã³ããããŠïŒæéåŸã«ã¢ã»ãã«ãµãªãã«é žïŒ
ã¯è¶ éå æçå¹æã瀺ãã è¬åŠçåŠæ¹ç© äžèšã®çæµè£ 眮ã«ããéèå 泚å°ã®ä»£ããã«ã
è¶ éå æçå¹æãéæããããã«çµå£ããã³çŽè ž
æäžã«é©åœã§ããæžæ¿ç©ããã³åºäœç¶åŠæ¹ç©ã䜿
çšããããšãã§ããã 人ã«æäžããããã®ãã®çš®ã®åŠæ¹ç©ã®äŸã¯ã¢ã»
ãã«ãµãªãã«é žïœmgãšçµåãããŠçŽç²ãªç©è³ªãšã
ãŠãã³ããã·ãã€ãªã³ãŸãã¯ä»ã®ããµã³ãã³èªå°
äœïŒå®æœäŸïŒã17åç §ïŒïœmgããã³ïŒãŸãã¯åæ¥
äžå ¥æå¯èœãªæçµåŠæ¹ç©ãã¢ã«ããŒã ã«ãŒã»ã«
ãã¢ãŒãGmbHããäŸçµŠããããã¬ã³ã¿ã«(R)
ïŒTrental(R)ãAlbert Roussel Pharma GmbH
ïŒãŠã€ãŒãºããŒãã³ïŒããäŸçµŠïŒãŸãã¯Dr.ã¬ã³ã
ãšã©ãŒã¢ã«ããã€ãããã«GmbHããäŸçµŠãã
ãã¬ã³ããªã³(R)ïŒRentylin(R)ãDrãRentschler
Arzneimittel GmbHïŒCo.ïŒã©ãŠããšã€ã ïŒãã
äŸçµŠïŒãïŒããããããã³ïŒ²ãšç¥ãïŒããŸãã¯ã
ããã®æçµåŠæ¹ç©ã®äžéšãå«æããããã®å Žåã¢
ã»ãã«ãµãªãã«é žãŸãã¯å¡©åºæ§ã€ãªã³äº€æäœïŒã
ãŠãšãã¯ã¹(R)ïŒÃïŒãããã³QAEâã»ãã¢ãã
ã¯ã¹(R)ïŒDowex(R)ããã³QAEâSephadex(R)ããµ
ãŒã瀟ïŒServaïŒãã€ãã«ãã«ã°ïŒããŸãã¯åžç
æš¹èãã¢ã³ããŒã©ã€ã(R) XAD2ïŒAmberlite(R)ïŒã
ãšçµåãããããšãã§ãããŸãåæ¥çã«å ¥æå¯èœ
ãªãã€ã¯ãã«ãã»ã«ãã³ã«ãã¢ãªãã(R)ããã€ã€
ãŒAG瀟ïŒColfarit(R)ãBayer AGïŒã¬ããŒã¯ã»
ã³ïŒãïŒïŒ£ãšç¥ãïŒãŸãã¯çµæ¶ãããŒã ãã¢ãŒã
GmbHããäŸçµŠãããR95Dããã³M80DïŒRohm
Pharma GmbHããã€ã¿ãŒã·ãŠã¿ããããã€
ãïŒãã®åœ¢æ ã§ãã€ãŠãããããããã®çµåãã
å€äžã®è¬åŠç賊圢å€ã¯å ç±ã«ããåºåããã²ã«ã§
ããïŒããªãã¡(a)æ°ŽäžãŒã©ãã³20ééïŒ ïŒã°ãªã»
ãªã³ïŒééïŒ ã(b)æ°Žäžã¢ã¬ããŒã¹ïŒééïŒ ããã
ã³(c)ã¢ã»ãã³ïŒæ°ŽïŒ80ïŒ20ééïŒ ïŒäžãšãã«ã»ã«
ããŒã¹T50ïŒãã«ã¯ã¬ã¹GmbHããã³ãã«ã°ïŒ10
ééïŒ ã§ãããããããã®å Žåã«ïŒééïŒ ã®ãã³
ããã·ãã€ãªã³ãŸãã¯ä»ã®ããµã³ãã³èªå°äœãæ¹
æäžã§å ããããŠãããããŸãã¯å ããããŠããª
ãïŒãããŸãã¯åæ¥äžå ¥æå¯èœãªãŒã©ãã³ã«ãã»
ã«ïŒäººããã³å€§ããåç©ã«æäžããããããµã€ãº
ïŒïŒã«ãã¹ã²ã«ç€ŸïŒKapsugelãããŒãŒã«ïŒã«ã
ãäŸçµŠïŒã§ããã ç¬ã®è液10mlãŸãã¯0.1Nå¡©é ž10mlã«äžèšã®è¬
åŠçåŠæ¹ç©ïŒå®æœäŸïŒã17åç §ïŒãå ãããããŠ
è©Šéšç®¡å ã§ç©åã«æ¹æããªãã37âã§ä¿æããã
äžæŸã¿æ¶²ã®äžå®éãç¹å®ã®æéééã§æãåãã
é«é液äœã¯ãããã°ã©ãã€ãŒãã«ã©ã ïŒã©ãã
ããã¯C18ãŠãªãŒã¿ãŒãºGmbHãšã·ãŠããŒã³ãã
ã€ãïŒRad Pak C18ãWaters GmbHïŒ100ÃïŒ
mmã10ÎŒïœã移åçžïŒã¡ã¿ããŒã«300mlïŒé ¢é žïŒ
mlãæ°Ž700mlãæµé1.5mlïŒåãã«ããåå¥ããã
ããã®æåã280nïœã«ãããUVæ€åºã«ããå®é
çã«æž¬å®ããããã®è¬åŠçåŠæ¹ç©ã¯åäºæè žæ¶²
ïŒç¬ïŒã«ããŸãã¯çé žæ°ŽçŽ ãããªãŠã 液ïŒPH7.4ïŒ
ã«åæ§ã®æ¹æ³ã§å ããããã å°åç©ã«æäžããããã«ã¯ïŒè¡šïŒã®ã©ãããå
ç §ïŒãå®æœäŸïŒã17ã«èšèŒãããåŠæ¹ç©ã®æåã
ãããã1/200ã®ééã«æžãããããŸãã¯ãµã€ãº
ïŒããã³ïŒã®ã«ãã»ã«ã䜿çšããã
ãè¡šã
ãè¡šã
ãè¡šã
ãè¡šã
ã«ã¢ã»ãã«ãµãªãã«é
ž
ïŒ1
ïŒ1
ãè¡šã
æ§ã®ãã€ã¯ãã«ãã»ã«åããã¢
ïŒ30
ã»ãã«ãµãªãã«é ž(M80D)
ïŒ30
ã»ãã«ãµãªãã«é ž(M80D)
ãè¡šã
ãè¡šã
âããµã³ãã³
ãè¡šã
ã³
ãè¡šã
ã³
120 20
120 20
Claims (1)
- åã®ççŽ ååãæããçŽéã¢ã«ãã«ãïŒÏâïŒïŒ
âãªããœã¢ã«ãã«ãŸãã¯ïŒÏâïŒïŒâãããã
ã·ã¢ã«ãã«åºã§ããããããŠä»ã®ïŒåã®åºR2
ããã³R3ããŸãã¯R1ããã³R2ã¯ããããR1ã
ãã³R3ã®äœçœ®ã«ïŒãïŒåã®ççŽ ååãããã
ãŠR2ã®äœçœ®ã«ïŒãïŒåã®ççŽ ååãæããçŽ
éãŸãã¯åæéã¢ã«ãã«åºã§ãããããã ãã
ããïŒã€ã®ã¢ã«ãã«çœ®æåºã«å«ãŸããççŽ åå
ã®åèšã¯æé«10ã§ãããã®ãšããïŒã®ããµã³ã
ã³èªå°äœããŸãã¯åŒ ïŒãã ãåŒäžãã¯ïŒãïŒåã®ççŽ ååãæã
ãã¢ã«ãã«åºã§ããïŒã®ããµã³ãã³èªå°äœããŸ
ãã¯åŒãŸãã¯ã®ãªããœã¢ã«ãã«ããµã³ãã³
ãŸãã¯åŒã®ããããã·ã¢ã«ãã«ããµã³ãã³ã®
ãããã©ãã°ãŸãã¯åŒãŸãã¯ã®ããµã³ãã³
èªå°äœã®ä»£è¬ç©ãããã³ (B) âã¢ã»ãã«ãµãªãã«é žãŸãã¯ãã®è¬çåŠç
ã«èš±å®¹ãããå¡©ãå«æãã (C) è¬åŠçæ äœãäžç·ã«å«æãããããŸãã¯å«æ
ããªãè¡æ¶²æåé害起å çŸæ£æ²»çå€ã ïŒ (A) åèšã®åŒãŸãã¯ãæããããµã³ãã³
èªå°äœãŸãã¯åŒãŸãã¯ã®ãªããœã¢ã«ãã«ã
ãµã³ãã³ãŸãã¯åŒã®ããããã·ã¢ã«ãã«ããµ
ã³ãã³ã®ãããã©ãã°ããŸãã¯åŒãŸãã¯ã®
ããµã³ãã³èªå°äœã®ä»£è¬ç©ãããã³ (B) âã¢ã»ãã«ãµãªãã«é žãŸãã¯ãã®è¬çåŠç
ã«èš±å®¹ãããå¡©ããããèªäœãããŸã㯠(C) è¬åŠçæ äœãšäžç·ã«éåžžã®æ¹æ³ã§ãããµã³ã
ã³èªå°äœ(A)ãå€åŽã®å±€ã«ããããŠæå(B)ãè¯éš
åã«ãŸãã¯ä»ã®å±€ã«å«ãŸãããããªå±€ç¶é å€ãŸ
ãã¯å€å±€é å€ãŸãã¯åå€ã«çµåãããããããŸ
ãã¯äžèšã®æåãã«ãã»ã«äžã§çµåããããŠã
ããããªç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æ²»çå€ã ïŒ ããµã³ãã³èªå°äœãåŒïŒãã ãåŒäžãR1
ãŸãã¯R3ã¯ïŒåãŸãã¯ïŒåã®ççŽ ååãæãã
ã¢ã«ãã«ãïŒÏâïŒïŒâãªããœã¢ã«ãã«ãŸãã¯ïŒÏ
âïŒïŒâããããã·ã¢ã«ãã«åºã§ããããããŠä»
ã®ïŒåã®ã¢ã«ãã«çœ®æåºR2ããã³R3ãŸãã¯R1ã
ãã³R2ã¯äžç·ã«ãªã€ãŠïŒãïŒåã®ççŽ ååãæ
ãããã®ãšããïŒãæããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒãŸ
ãã¯ç¬¬ïŒé èšèŒã®æ²»çå€ã ïŒ ããµã³ãã³èªå°äœã®R1ãŸãã¯R3ãããã·ã«ã
ïŒâãªããœããã·ã«ãŸãã¯ïŒâããããã·ããã·
ã«åºãè¡šãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æ²»ç
å€ã ïŒ åèšããµã³ãã³èªå°äœãïŒâããã·ã«âïŒïŒ
ïŒâãžã¡ãã«ããµã³ãã³ãïŒâïŒïŒâããããã·
ããã·ã«ïŒâïŒïŒïŒâãžã¡ãã«âããµã³ãã³ãïŒ
âïŒïŒâãªããœããã·ã«ïŒâïŒïŒïŒâãžã¡ãã«âã
ãµã³ãã³ãïŒïŒïŒâãžã¡ãã«âïŒâïŒïŒâããã
ãã·ããã·ã«ïŒâããµã³ãã³ãïŒïŒïŒâãžã¡ãã«
âïŒâïŒïŒâãªããœâããã·ã«ïŒâããµã³ãã³ãïŒ
âïŒïŒâããããã·ããã·ã«ïŒâïŒâã¡ãã«âïŒâ
ãããã«âããµã³ãã³ãŸãã¯ïŒâïŒïŒâãªããœã
ãã·ã«ïŒâïŒâã¡ãã«âïŒâãããã«ããµã³ãã³
ã§ãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æ²»çå€ã ïŒ äžèšã®ããµã³ãã³èªå°äœã¯ãå°ãªããšãïŒå
ã®ã«ã«ããã«åºãåŒ ïŒãã ãåŒäžãR4ããã³R5ã¯ããããïŒåãŸã§
ã®ççŽ ååãæããã¢ã«ãã«åºãè¡šãããããŸã
ã¯R4ããã³R5ã¯äžç·ã«ãªã€ãŠãšãã¬ã³ãããªã¡
ãã¬ã³ãŸãã¯ããã©ã¡ãã¬ã³åºãè¡šããïŒã®æ§é
èŠçŽ ã«ãã眮æãããŠãããããªã¢ã»ã¿ãŒã«åã
ãããªããœã¢ã«ãã«ããµã³ãã³ãšããŠãããã©ã
ã°ã®åœ¢æ ã§ååšãããããŸãã¯åŒR6âCOââ
ïŒïŒïŒãã ãåŒäžãR6ã¯ïŒåãŸã§ã®ççŽ ååã
æããã¢ã«ãã«åºãŸãã¯ããšãã«ã眮æãããã
ãšãã«ãããªãžã«ãŸãã¯çœ®æãããããªãžã«ãè¡š
ããïŒã®æ§é èŠçŽ ãæããâã¢ã·ã«åãããã
ãããã·ã¢ã«ãã«ããµã³ãã³ã§ãããç¹èš±è«æ±ã®
ç¯å²ç¬¬ïŒãïŒé ã®ããããã«èšèŒã®æ²»çå€ã ïŒ è£œå€ã奜ãŸããã¯ãã³ããã·ãã€ãªã³100ã
600mgãç¹ã«200ã400mgããã³ã¢ã»ãã«ãµãªãã«
é ž10ã2000mgãŸãã¯åœéã®ãã®å¡©ãå«æãããçµ
å£çã«ããéçµå£çã«ããŸãã¯çŽè žã«æäžããã
ãã®è¬éåäœåœ¢æ ã§ååšãããç¹èš±è«æ±ã®ç¯å²ç¬¬
ïŒãïŒé ã®ããããã«èšèŒã®æ²»çå€ã ïŒ ã¢ã»ãã«ãµãªãã«é žïŒééæ¯ã«å¯Ÿããããµã³
ãã³èªå°äœã®ééæ¯ã0.1ã50ã奜ãŸããã¯0.5ã
50ããããŠç¹ã«ïŒã10ã®ç¯å²å ã§ãããç¹èš±è«æ±
ã®ç¯å²ç¬¬ïŒãïŒé ã®ããããã«èšèŒã®æ²»çå€ã ïŒ æå(B)ã§ããã¢ã»ãã«ãµãªãã«é žã«å¯Ÿããæ
äœãé 延äœçšãäžããè¬å€ãå«æãããç¹èš±è«æ±
ã®ç¯å²ç¬¬ïŒãïŒé ã®ããããã«èšèŒã®æ²»çå€ã ïŒïŒ ã¢ã»ãã«ãµãªãã«é žæåãå«æããã«ãã»
ã«ã®ç©è³ªãè液ã«å¯ŸããŠæµææ§ã®ãããã®ã§ãã
ããæŸåºãé ããããããªãã€ã¯ãã«ãã»ã«ã®åœ¢
æ ã§ãã®è£œå€ãååšãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒã
ïŒé ã®ããããã«èšèŒã®æ²»çå€ã ïŒïŒ ããµã³ãã³èªå°äœãæåã«æº¶è§£ãã¹ãå±€ã«
å«ãŸããŠãããããªå±€ç¶é å€ãŸãã¯å€å±€é å€ã®åœ¢
æ ã§ãã®è£œå€ãååšãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒã
ïŒé ã®ããããã«èšèŒã®æ²»çå€ã
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3426961 | 1984-07-21 | ||
| DE3426961.4 | 1984-07-21 | ||
| DE3508097.3 | 1985-03-07 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4290135A Division JPH0749374B2 (ja) | 1984-07-21 | 1992-10-28 | æççå€ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6137785A JPS6137785A (ja) | 1986-02-22 |
| JPH0529014B2 true JPH0529014B2 (ja) | 1993-04-28 |
Family
ID=6241240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP15848185A Granted JPS6137785A (ja) | 1984-07-21 | 1985-07-19 | ããµã³ãã³èªå°äœãšïœâã¢ã»ãã«ãµãªãã«é žãããªãè¡æ¶²æåé害起å çŸæ£æ²»çå€ |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JPS6137785A (ja) |
| DE (1) | DE3515874A1 (ja) |
| ZA (2) | ZA855457B (ja) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3623331A1 (de) * | 1986-07-11 | 1988-01-21 | Hoechst Ag | Konfektionspackungen, enthaltend arzneimittelkombinationen fuer zeitlich abgestufte anwendung |
| DE3717337A1 (de) * | 1987-05-22 | 1988-12-15 | Hoechst Ag | Verfahren zum nachweis der antiaggregatorischen wirkung von vasoaktiven stoffen, speziell von phosphodiesterase- und/oder cyclooxygenase-hemmern |
-
1985
- 1985-05-03 DE DE19853515874 patent/DE3515874A1/de not_active Withdrawn
- 1985-07-19 ZA ZA855457A patent/ZA855457B/xx unknown
- 1985-07-19 ZA ZA855458A patent/ZA855458B/xx unknown
- 1985-07-19 JP JP15848185A patent/JPS6137785A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| DE3515874A1 (de) | 1986-01-23 |
| ZA855457B (en) | 1986-03-26 |
| JPS6137785A (ja) | 1986-02-22 |
| ZA855458B (en) | 1986-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4880791A (en) | Combination product composed of xanthine derivatives and O-acetylsalicylic acid or its pharmacologically tolerated salts, and its use | |
| JP5757677B2 (ja) | éèå§äº¢é²çã®äºé²åã³ïŒåã¯æ²»ç | |
| Clissold | Aspirin and related derivatives of salicylic acid | |
| US7148208B2 (en) | Pharmaceutical compositions for headache, migraine, nausea and emesis | |
| US4694024A (en) | Combination product composed of pyrimido-pyrimidines and O-acetylsalicylic acid or its pharmacologically tolerated salts, and its use | |
| JP2024019691A (ja) | èºåèæ§é«è¡å§çããã³ä»çŸæ£ã«é¢é£ããèºåèæ§èºé«è¡å§çã®æ²»çæ³ | |
| JPH0352815A (ja) | è¡ç®¡å è¡æ¶²ååºçå矀ã®æ²»çå€ | |
| KR20050100676A (ko) | ììžížìŽëŠ¬ì€ì° ë° ìì§ì€í ì â ± êžžíì ì ë°°í©ëëíŒëŠ¬ë€ëª°ì ëì¡žì€ ìë°©ì ìí ì©ë | |
| CA2294095C (en) | Synergistically acting compositions for selectively combating tumor tissue | |
| JPS6137785A (ja) | ããµã³ãã³èªå°äœãšïœâã¢ã»ãã«ãµãªãã«é žãããªãè¡æ¶²æåé害起å çŸæ£æ²»çå€ | |
| Molkara et al. | Chronic ergot toxicity presenting with bilateral external iliac artery dissection and lower extremity rest pain | |
| MX2010010869A (es) | Agente para prevenir y/o tratar enfermedades vasculares. | |
| JPH0410446B2 (ja) | ||
| Boullin et al. | Effects of aspirin and prostaglandin E2 on secondary phase aggregation responses of schizophrenic patients treated with chlorpromazine. | |
| Ferrara et al. | Once a Day Indapamide Therapy in Hypertension Effects on the Heart and Peripheral Arterial Circulation | |
| JPH0333126B2 (ja) | ||
| JPH04342526A (ja) | åè¢ã®æ«æ¢¢åŸªç°æ¹åå€åã³è¡ç®¡æ£çž®æå¶å€ | |
| JP2005060359A (ja) | è¡ç®¡ç³»ç æ ã®æ²»çåã³äºé²ã®ããã®ãžããªãã¢ãŒã«ãã¢ã»ãã«ãµãªãã«é žåã³ã¢ã³ã®ãªãã³ã·ã³ïœïœæ®æè¬ã®äœ¿çš | |
| JPH051244B2 (ja) | ||
| Van Dyke et al. | Drugs Used in Gout | |
| Samama et al. | EFFECT OF ASPIRIN AND ASPIRIN COMBINED WITH DIPYRIDAMOLE IN EARLY DIABETIC RETINOPATHY | |
| JPS6210015A (ja) | è¡å°æ¿éåæå¶ç©è³ªã®çµåãè£œå€ | |
| CA2437709A1 (en) | Use of dipyridamole, acetylsalicylic acid and an angiotensin ii antagonist for treatment and prevention of vascular events | |
| JPH04164033A (ja) | å¿èçŸæ£ã®äºé²ãŸãã¯æ²»çå€ | |
| MXPA03007462A (es) | Uso de dipiridamol, acido acetilsalicilico y un antagonista de la angiotensina ii para el tratamiento y la prevencion de eventos vasculares. |